always active healthy feel great finally like carol willis annual report mission clear discover develop deliver innovative medicines help patients prevail serious diseases sense urgency real work every day push boundaries scientific discovery make meaningful difference lives patients committed developing st century workforce powerfully diverse broadly inclusive capable discovering developing important new medicines patients around world patient stories shared annual report depict individual patient responses medicines investigational compounds representative patient responses addition guarantee potential drugs indications still development receive regulatory approvalat bristolmyers squibb employees like mina chaudhry austin thekkumthala passionate turning scientific insights new therapeutic options many patients need bristolmyers squibb annual report bristolmyers squibb looking forward exciting future build strong foundation grow business help patients great medicines great people giovanni caforio md chairman board nd chief executive officer bristolmyers squibb come work every day one highly competitive markets opdivo approved nine mission mind discover develop deliver transformational tumor types indications opdivo revenue grew medicines help patients facing serious diseases percent ending year billion global sales opdivo continues maintain grow market share approved indications expanding new tumors earlier performance strong across company created lines therapy saw significant growth launch great momentum business expanded indications opdivo adjuvant treatment melanoma approval oncology portfolio important approval opdivo opdivo plus lowdose yervoy treatment first line rcc plus lowdose yervoy treatment renal cell carcinoma us additionally opdivo plus lowdose yervoy approved rcc us europe reached important milestone european medicines agency first line rcc january eliquis us taking leadership position prevention expanding immunooncology io combination stroke patients atrial fibrillation advanced broad therapy treatment option patients rcc markets deep pipeline oncology cardiovascular disease fibrosis across europe immunoscience continued efforts good global citizen green initiatives investing opdivo distinguished first immunooncology therapy local communities supporting need approved china milestone tribute focused efforts teams us china ensure speed results delivering important medicine cancer patients china marked outstanding commercial execution ended year billion revenues nine percent global sales increase due growth nearly priority medicines results translate directly medicines delivered patients strong operating performance europe resulted gaap earnings per share united nongaap earnings per share represents states yearoveryear growth percent transforming cancer care remains priority company focus increasing survival rates patients across greater rest range tumor types oncology franchise performed well world troper launna bbiuqs sreymlotsirb opdivo growth b priority delivering brands medicines billion revenue eliquis orencia patients revenue growth b yervoy vs empliciti eliquis continued grow us internationally made significant progress advancing revenues totaling billion representing percent innovative medicines pipeline includes clinical programs increase achieved major milestone immunoscience fibrosis cardiovascular disease results new prescriptions eliquis surpassed warfarin phase study selective tyk inhibitor treatment previous standard care stroke prevention atrial fibrillation moderate severe plaque psoriasis published new become number one prescribed oral anticoagulant england journal medicine september registrational us eliquis continues leading novel oral trials indication well underway continue advance anticoagulant globally stroke prevention patients fibrosis portfolio lead compound area fgf atrial fibrillation treatment nonalcoholic steatohepatitis nash currently enrolling phase b trial heart failure research eliquis clinical profile supported continued nitroxyl donor asset currently phase trials look investment realworld data analysis published forward data readouts coming year additionally acropolis apixaban experience realworld signed collaboration agreement janssen pharmaceuticals population studies study includes one development factor xia inhibitor secondary million patient records largest body realworld stroke prevention initiated phase trial evidence existence analyzing effectiveness safety anticoagulants including eliquis among patients nonvalvular broad development program oncology includes atrial fibrillation venous thromboembolism important growing body work translational medicine giving us greater insights patients benefit proud medicine discovered developed medicines opened new research center bristolmyers squibb scientists three received cambridge massachusetts focus resistance treatment prestigious sir james black award british current immunooncology agents look forward pharmacological society contributions discovery leveraging rich scientific ecosystem location drive eliquis innovation field delivering tomorrow clinical programs focused expanding benefits immunooncology portfolio moving earlier lines scientists bristolmyers squibb understand urgent therapy including adjuvant setting follows surgery needs patients new treatment options hard work prevent recurrence next generation transformational medicines patients continue invest research development new expect see number data readouts lung treatment options address significant unmet medical needs cancer program well studies opdivo treatment bristolmyers squibb annual reportpage global diversity inclusion people business resource groups people business resource groups pbrg leverage diverse experiences perspectives employees drive transformative business results total pbrgs membership k unique members glioblastoma head neck liver renal delivering underserved cancers starting begin see chapters communities results studies adjuvant treatment bring greater understanding role throughout year bristolmyers squibb opdivo earlier stages disease foundation continued build capacity include results adjuvant melanoma bladder expand access care underserved esophageal cancers next year results populations supporting innovative programs present tumors renal liver lung train health care providers mobilize cancers coming subsequent years communities fight disease innovation focus believe effort included extensive programs countries tomorrows medicines come us remove barriers increase internal efforts well rich access specialized care vulnerable ecosystem scientific innovation exists populations improve lung cancer awareness outside company business care support reintegration development teams hard work find returning veterans families also medicines year entered included significant innovations access global strategic collaboration jointly develop cardiovascular care commercialize nektar therapeutics bristolmyers squibb foundation also lead immunooncology program nktr combination opdivo opdivo working bring quality cancer treatment plus yervoy nektar program provides african communities focusing cervical bristolmyers squibb third validated lung cancer southern east africa mechanism immunooncology providing us pediatric cancers southern east africa cultivating leadership innovation opportunity build experience west africa leveraging extensive millennials beyond opdivo yervoy learnings years secure future program first largest private january announced definitive initiative address hiv aids southern merger agreement planned acquisition east africa foundation working celgene corporation transaction community partners promote cancer create leading focused specialty biopharma screening train healthcare providers company well positioned address lesbian gay bisexual transgender allies change outcomes cancer patients needs patients cancer inflammatory following launch project echo immunologic disease cardiovascular cancer us foundation funding disease highvalue innovative expansion telementoring program medicines leading scientific capabilities rural hospitals south africa complementary areas focus combined company operate global recognize helping improve access reach scale maintaining speed medicines critical importance agility core companys strategic ensure patients benefit innovations approach bristolmyers squibb patient transaction subject approval bristolmyers squibb celgene shareholders satisfaction customary closing conditions regulatory approvals bristolmyers squibb celgene expect complete transaction third quarter troper launna bbiuqs sreymlotsirbas regaining strength carol resumed favorite activities woodworking passion shares uncle jerry patient story built fight carol willis always active healthy feel great finally like april carol willis certain patients advanced retired school teacher renal cell carcinoma rcc whose oakdale la mother kidney cancer spread three grown children experiencing initial developed nagging cough side effects excellent discovered mass response opdivo right side yervoy combination recalls carol noticed remission carol losing weight difficulty clean scans since january focusing thoughts becoming easily fatigued showing mass always active healthy daughter nurse practitioner feel great finally like immediately saw urologist says ct scan getting sick changes priorities carol says fam selfdescribed private person ily closer ever four generations left grand doctor confirmed daughter madelyn mother vivian carol daughter mindy carol enjoys quiet life style kidney cancer says resumed specialists told stage iv renal cell carcinoma hobby woodworking also travels often spend soon surgery remove large tumor time children six grandchildren texas followup appointment doctor explained colorado despite surgery carols cancer spread lungs past years opportunity meet liver point referred oncologist speak number bristolmyers squibb employees principal investigator clinical trial thats carol says ive heard many personal stories knew really serious says passionate help patients entered clinical trial investigating opdivo werent skill dedication wouldnt combination another io treatment yervoy enjoy life bristolmyers squibb annual report bristolmyers squibb achievements assistance foundation uninsured patients facing financial hardships able obtain medicines need respect integrity quality fight serious disease work commitment good citizenship extends beyond medicines communities impacted natural disasters year brought take great pride devastation wildfires california hurricanes north carolina grateful florida floods landslides japan earthquake recognition received including tsunami indonesia bristolmyers squibb foundation responded quickly cash donations disaster relief partners provide essential supplies company donated muchneeded products th year perfect help impacted communities score corporate equality index cei continued work united nations global compact well go green activities bristolmyers squibb sites promote sustainability environmental programs recognized ranked topscoring energy star partner year sustained excellence award company disability four consecutive years efforts improve energy efficiency equality index facilities worldwide dow jones north strengthening company culture american index leading sustainable companies bristolmyers squibb best brightest people fuel success hard work commitment second year row able realize mission help patients fighting serious disease careerbliss top happiest companies america committed creating sustaining strong culture inclusion foster highly innovative work environment people business resource groups pbrgs leverage diverse experiences perspectives employees drive transformative business working mother results members pan asian network partnered best companies rd organization china launch global buddy system designed th consecutive year mentor colleagues new clinical development china resulting accelerated launch opdivo additionally lgbta pbrg introduced bestofthebest set transgender guidelines us ensure respectful corporations inclusion inclusive workplace environment employees process national business inclusion gender transition consortium embedded throughout culture deep commitment integrity uncompromising ethics work ensure highest ethics military friendly company integrity foundation showcasing powerful effective military programs looking forward workplace bristolmyers squibb looking forward exciting future build strong foundation grow business crs best corporate citizens bestcorporate help patients great medicines great people citizens th consecutive year focusing patients families demanding best people possibilities endless continue create value patients shareholders employees forbes capitals excited future companies america thank energy star partner year sustained excellence award giovanni caforio md chairman board chief executive officer ranked among top pharmaceutical companies innovation quality april management nafe top companies executive women troper launna bbiuqs sreymlotsirb patient story experiencing benefits ken simpson benefits ive received eliquis greater peace mind ability continue live full life loved ones ken simpson nationally ranked cardiologist continued high school american swimmer checked periodically earned athletic years passed kens condition scholarship university illinois gradually worsened mids wasnt many years cardiologist removed blood college graduation first clot top left anterior experienced heart problems descending artery fortunate would come go next survived procedure years several years later daylong spent almost entire business career business meeting chicago wm wrigley jr company ken grateful second chances considers found couldnt walk train chicago ken says one day lucky reconnected childhood station without stopping several work felt strange feeling chest sweetheart beverly years apart times knew wasnt going make never didnt know wha knew something wasnt quite right station obvious something wrong wrigley family separately owned chicago cubs baseball emergency room ekg first identified kens condition team time ken sent see team doctor familiar diagnosed atrial fibrillation type irregular working accomplished athletes prescribed heart heartbeat caused heart valve problem cardiologist monitor wear month irregularities found immediately prescribed eliquis reduce increased risk stroke patients kens condition face late ken began swimming national masters swimming program adults one competition strange take eliquis religiously every morning every night feeling chest returned make sure dont miss dose ken says wasnt flutter skipped heartbeat like thunderous nowretired businessperson saying sell steady heartbeat explains decided wasnt going live benefits product advice life afraid heart condition apparently couldnt sell successfully diagnosed swam race winning time got matter product whats important pool strange heartbeat gone benefits provides user ken says benefits another heart monitor showed irregularity ken ive received eliquis greater peace mind convinced something wrong began seeing ability continue live full life loved ones bristolmyers squibb annual reportbristolmyers squibb development portfolio therapeutic area oncology phase phase ii phase iii approved indications opdivo opdivo opdivo opdivo solid tumors l crc l glioblastoma l braf wildtype metastatic hematologic malignancies melanoma nonhodgkin lymphoma l hcc opdivo yervoy diffuse large bcell adjuvant melanoma l head neck lymphoma solid tumors advanced hodgkin lymphoma l head neck locally nonhodgkin lymphoma relatlimab advanced melanoma across braf status follicular lymphoma solid tumors l esophageal mesothelioma ovarian hematologic malignancies adjuvant bladder previously treated advanced pan tumor tmb high nlrp agonist rcc adjuvant esophageal pediatric solid tumors gastroesophageal previously treated gastric primary testicular cancer jpn antitim adjuvant gastric lymphoma previously treated hcc solid tumors adjuvant hcc opdivo previously treated metastatic humaxil adjuvant rcc solid tumors head neck solid tumors nsclc neoadjuvant opdivo yervoy previously treated metastatic ep antagonist refractory hodgkin melanoma prostate lymphoma solid tumors previously treated metastatic opdivo yervoy unresectable nsclc msihigh crc cdcd oncolytic solid tumors virus opdivo yervoy previously treated metastatic relatlimab opdivo nonsquamous nsclc solid tumors l bladder solid tumors previously treated metastatic antictla probody l esophageal squamous nsclc ido opdivo solid tumors l gastric previously treated metastatic solid tumors antiicos l head neck sclc nktr opdivo solid tumors l mesothelioma previously treated metastatic solid tumors urothelial antictla nf l nsclc ccr dual antagonist opdivo yervoy solid tumors l sclc solid tumors l rcc antitigit adjuvant melanoma cabiralizumab braf wildtype metastatic solid tumors adjuvant rcc melanoma solid tumors anticd nsclc egfr mutant melanoma across braf status solid tumors opdivo yervoy previously treated metastatic cabozantinib bet inhibitor msihigh crc metastatic rcc solid tumors yervoy opdivo empliciti ulocuplumab adjuvant melanoma multiple myeloma hematologic malignancies adolescent metastatic opdivo ido melanoma l metastatic melanoma metastatic melanoma neoadjuvant muscle empliciti invasive bladder cancer relapsedrefractory multiple opdivo nktr myeloma pomalyst combo l melanoma relapsedrefractory multiple myeloma revlimid combo l st line l rcc l nd line relatlimab opdivo sprycel cml chronic myelogenous leukemia l cml crc colorectal cancer l melanoma hcc hepatocellular carcinoma empliciti pediatric nsclc nonsmall cell lung cancer refractory cml rcc renal cell carcinoma l multiple myeloma sclc small cell lung cancer revlimid combo troper launna bbiuqs sreymlotsirbbristolmyers squibb development portfolio therapeutic area immunoscience phase phase ii phase iii approved indications rort tyk inhibitor orencia orencia autoimmune disease autoimmune diseases idiopathic inflammatory early rheumatoid arthritis myopathy sp agonist btk inhibitor juvenile idiopathic sjgrens disease arthritis intravenous autoimmune disease rheumatoid arthritis tyk inhibitor juvenile idiopathic btk max arthritis subcutaneous psoriasis rheumatoid arthritis psoriatic arthritis nulojix tyk inhibitor rheumatoid arthritis switch autoimmune disease auto injector calcineurin inhibitor tlr antagonist renal transplant rheumatoid arthritis intravenous autoimmune disease rheumatoid arthritis subcutaneous nulojix de novo renal transplant cardiovascular phase phase ii phase iii approved indications fpr agonist nitroxyl donor eliquis eliquis heart failure heart failure pediatric venous stroke prevention thromboembolism atrial fibrillation apj agonist factor xia inhibitor prevention venous thromboembolism heart failure thrombosis prevention orthopedic eliquis surgery pediatric heart disease venous thromboembolism treatment fibrotic diseases phase phase ii lpa antagonist hsp fibrosis fibrosis pegbelfermin pegfgf nonalcoholic steatohepatitis note pipeline excludes clinical collaborations trials exploring various combinations partnerrun study development partnership opdivo yervoy relatlimab ep ono collaboration ono also includes early stage compounds empliciti abbvie nktr nektar cabiralizumab five prime cabozantinib exelixis eliquis pfizer factor xla inhibitor janssen hsp nitto denko pomalyst revlimid trademarks celgene corporation listed tables investigational compounds clinical studies well approved potential indications marketed products related therapeutic area january whether listed compounds ultimately becomes marketed product depends results clinical studies competitive landscape potential products market reimbursement decisions payers manufacturing processes necessary produce potential product commercial scale among factors assurance seek regulatory approval compounds approval sought obtained also assurance compound gets approved commercially successful stage development determine intellectual property issues patent protection may may available investigational compounds bristolmyers squibb annual report secure future th anniversary since inception secure future oversaw investment million programs trained twenty years ago world prepared tens thousands health care providers increased capacity care welcome new millennium hospitals clinics raised awareness hiv prevention million people living hivaids increased communitybased support children families virus two thirds million affected disease people countries subsaharan africa secure futures impact pediatric care landmark women children initiative brought together foundation bipai transmission rates subsaharan countries rise governments five subsaharan countries botswana lesotho access adequate care lowest world resources eswatini uganda tanzania create largest pediatric hiv extremely limited hivaids become leading treatment network world date bipai treated cause death threatening regions future million children currently directly care global pharmaceutical company strong portfolio percent teenagers adolescents hiv therapies bristolmyers squibb took major role today secure futures focus evolved help address fight disease together african continents next major health challenge cancer many people bristolmyers squibb foundation company launched hiv living longer dying virus rather secure future groundbreaking commitment noncommunicable diseases hypertension cancer helped transform healthcare delivered region secure future created partnerships based years collaborations partnerships governments experience hiv also address lung cervical breast international agencies including world health pediatric cancers blood disorders organization unaids baylor international pediatric aids bipai texas childrens hospital cancer hematology initiative bipai well nongovernmental community centers bristolmyers squibb foundation launched global faith based organizations secure future created hope hematologyoncology pediatric excellence first model care hiv sustainable comprehensive program treat children cancer blood could replicated applied disease areas disorders hiv disparities cancer care africa started secure future looked parts world significant us pediatric cancer build local national capacity help inform countries survival rate percent compared mortality rate high hivaids plans develop lessons experiences percent africa addressing health disparities among women children secure future innovated models care across various therapeutic areas says john damonti delivery building capacity local african health professionals president bristolmyers squibb foundation care treat children women lifethreatening disease partnerships programs helped restore hope says phangisile mtshali director bristolmyers squibb foundation children families living hivaids gave lessons learned extended reach subsaharan communities subsaharan africa confidence africa creating communitybased treatment support programs resources needed properly care patients helped deliver antiretroviral therapy rural hardtoreach areas partnership global tb programme influential shaping policy practice around monitoring reporting community efforts finding missing tuberculosis cases taking lessons learned applying address pediatric lung cervical cancers robbing africa brighter future gains made hiv successes troper launna bbiuqs sreymlotsirb secure future th anniversary leg acy hope bristolmyers squibb annual report patient story every day live jessie stern faith prayer strength every day live jessie stern driving home candidate immuno car rearended stop sign oncology therapy jessies doctor following weekend jessie prescribed opdivo retired mother grandmother months receiving harrisburg pa began feeling treatment jessie began see pains abdomen visited improvement tumors local emergency room received shrinking examination included mri xray latest set jessies scans come back clear detectable turned nothing sign cancer physically wrong car accident jessie smoker selfdescribed people person past years says doctors jessie admits struggling noticed abnormality one depression learning jessies friend deborah side throughout fight lungs looking scans providing strength hope even laughter along way cancer stayed strong tried scheduled biopsy specialist positive says along said stage iii lung cancer says prayer got jessie suffering nonsmall cell lung cancer nsclc today exercises gym watches diet common type lung cancer makes past shares story cancer patients percent cases according national cancer institute support group oncologists office believing better hear deal cancer someone first jessie treated chemotherapy radiation experienced treatments werent working second chemotherapy tried jessie didnt like way treatments made feel jessie feeling good looking forward future without asked stop treatment oncologist suggested look cancer faith prayer strength says every different option biopsies doctor determined day live troper launna bbiuqs sreymlotsirbbristolmyers squibb financial report managements discussion analysis financial condition results operations quantitative qualitative disclosures market risk consolidated financial statements notes consolidated financial statements reports management controls procedures reports independent registered public accounting firm performance graph five year financial summary summary abbreviated terms board directors leadership team stockholder information bristolmyers squibb managements discussion analysis financial condition results operations executive summary bristolmyers squibb company global specialty biopharmaceutical company whose mission discover develop deliver innovative medicines help patients prevail serious diseases refer summary abbreviated terms end terms used throughout document received approvals new medicines additional indications formulations currently marketed medicines major markets us eu japan china including multiple regulatory milestone achievements opdivo opdivoyervoy combinations committed investigating opdivo alone combination yervoy anticancer agents wide array tumor types including broad programs lung head neck liver kidney bladder stomach continue believe breadth depth io portfolio positions us well future new io compounds clinical development studies across different tumor types addition advanced certain nonio rd programs pipeline including tyk inhibitor treatment psoriasis autoimmune diseases factor xia inhibitor treatment thrombosis collaboration janssen pegbelfermin pegfgf treatment nash revenues increased result higher demand prioritized brands including opdivo eliquis partially offset increased competition established brands primarily hiv brands daklinza increase gaap eps primarily due tax charges attributed tax reform higher revenues items partially offset higher losses equity investments adjusting impact tax reform equity investment losses specified items nongaap eps increased primarily result higher revenues higher royalties licensing income lower effective tax rate cost savings resulting transformation initiatives continue redeployed rd areas higher priorities january announced entered definitive merger agreement celgene acquire celgene discussion pending acquisition celgene acquisitions divestitures licensing arrangements refer consolidated financial statementsnote acquisitions divestitures licensing arrangements note subsequent event revenues increased result higher demand prioritized brands including opdivo eliquis partially offset increased competition established brands primarily daklinza decrease gaap eps due tax charges attributed tax reform per share lesser extent higher license asset acquisition restructuring related charges lower divestiture related income items partially offset higher revenues royalties licensing income patentinfringement settlement adjusting impact tax reform specified items nongaap eps increased primarily result higher revenues partially offset product mix higher rd expenses supporting opdivo io programs highlights following table summarizes financial information year ended december dollars millions except per share data total revenues diluted earnings per share gaap nongaap nongaap financial measures including nongaap earnings related eps information adjusted exclude specified items represent certain costs expenses gains losses items impacting comparability financial results detailed listing specified items information reconciliations nongaap financial measures refer nongaap financial measures annual report significant product pipeline approvals following summary significant approvals received product date approval august approval japan patients mpm progressed chemotherapy august approval japan adjuvant treatment melanoma fda approval first io treatment option patients metastatic sclc august whose cancer progressed platinumbased chemotherapy least one line therapy opdivo ec approval adjuvant treatment adult patients melanoma involvement july lymph nodes metastatic disease undergone complete resection approval china treatment locally advanced metastatic nsclc prior june platinumbased chemotherapy adult patients without egfr alk genomic tumor aberrations approval japan opdivo plus lowdose yervoy treatment unresectable august metastatic rcc fda approval opdivo plus lowdose yervoy treatment adult pediatric july patients years older msih dmmr mcrc progressed following opdivoyervoy treatment fluoropyrimidine oxaliplatin irinotecan approval japan opdivoyervoy combination previously untreated patients may unresectable melanoma fda approval opdivoyervoy combination previously untreated patients april intermediate poorrisk advanced rcc approval japan intravenously administered treatment moderate severe orencia february polyarticular jia patients two years age older fda approval empliciti injection intravenous use combination pomalidomide empliciti november dexamethasone treatment adult patients multiple myeloma received least two prior therapies including lenalidomide proteasome inhibitor fda expanded indication sprycel include treatment pediatric patients one december year age older newly diagnosed philadelphia chromosomepositive combination chemotherapy sprycel ec expanded indication sprycel include treatment children adolescents july aged year years chronic phase philadelphia chromosomepositive cml include powder oral suspension ec approval advanced unresectable metastatic melanoma pediatric patients yervoy january years age older refer product pipeline developments developments marketed products latestage pipeline early bristolmyers squibb strategy focus specialty biopharmaceutical company discovering developing delivering transformational medicines address serious unmet medical needs strategy combine resources scale capability pharmaceutical company speed focus innovation biotech industry four strategic priorities drive business performance continue build leading franchise io maintain diversified portfolio within outside io continue disciplined approach capital allocation including establishing partnerships collaborations inlicensing acquiring investigational compounds essential component successfully delivering transformational medicines patients developing new medicines following core therapeutic areas oncology priority certain tumor types immunoscience priorities psoriasis lupus ra inflammatory bowel disease cardiovascular priority heart disease fibrotic disease priorities lung liver continue advance next wave innovative medicines investing significantly pipeline internally business development activities expect planned acquisition celgene position us leading biopharmaceutical company expanding oncology immunoscience portfolios several nearterm assets additional external partnerships continue invest io portfolio pursuing monotherapy combination approaches advancing next wave early assets entered several new collaboration agreements across therapeutic areas focus expanded others research develop opdivo approved investigational oncology agents combination regimens remain focused wellresourced cancer development programs seek broaden use opdivo earlier lines therapy expand new tumors accelerate next wave io mechanisms develop treatment options refractory io patients beyond cancer continue advance early stage portfolio immunoscience cardiovascular fibrotic diseases strengthen partnerships diverse group companies academic institutions new expanded research activities believe differentiated internal external focus contributes advancing pipeline potentially transformational medicines commercial model evolving revenues prioritized brands continue grow demonstrates strong execution strategy continue drive growth opdivo expanding additional indications tumor types monotherapy combination yervoy anticancer agents eliquis continues grow leveraging best class clinical profile extensive real world data number one novel oral anticoagulant total prescriptions us building continued success prioritized brands remain strongly committed orencia sprycel operating model transformation commercial infrastructure uniquely leveraged potential growth operating model continues evolve successful focusing commercial rd manufacturing resources prioritized brands markets strengthening rd capabilities tumor biology patient selection new biomarkers delivering leaner administrative functions streamlining manufacturing network reflect importance biologics current future portfolio evolution operating model focuses maintaining disciplined approach marketing selling administrative expenses enable us deliver necessary strategic financial operational flexibility invest highest priority opportunities within portfolio looking ahead continue implement biopharma strategy driving growth prioritized brands executing product launches investing diverse innovative pipeline aided strategic business development focusing prioritized markets increasing investments biologics manufacturing capabilities maintaining culture continuous improvement acquisitions divestitures licensing collaboration arrangements acquisitions divestitures licensing collaboration arrangements allow us focus resources behind growth opportunities drive greatest longterm value focused following core therapeutic areas oncology including io immunoscience cardiovascular fibrosis significant acquisitions divestitures licensing collaboration arrangements past three years summarized refer consolidated financial statementsnote alliances note acquisitions divestitures licensing arrangements information arrangements nektar bms nektar commenced worldwide license collaboration development commercialization nktr nektars investigational immunostimulatory therapy janssen bms janssen commenced worldwide collaboration development commercialization factor xia program including bmss factor xia inhibitor bms investigational anticoagulant compound studied prevention treatment major thrombotic conditions annual report promedior bms notified promedior company would exercising warrant obtained purchase outstanding shares promedior rigel bms notified rigel pharmaceuticals inc company would discontinue participation preclinical collaboration cancer immunotherapies based rigel 's small molecule tgf beta receptor kinase inhibitors originally commenced bavarian nordic bms notified bavarian nordic company exercising option globally license commercialize prostvac bavarian nordics investigational psatargeting cancer immunotherapy arrangements ono bms acquired exclusive license develop commercialize ono onos prostaglandin e receptor antagonist treatment cancer bms acquired worldwide rights except japan south korea taiwan added existing collaboration china asean countries ono retained exclusive rights halozyme bms halozyme entered global collaboration license agreement develop subcutaneously administered bms io medicines using halozyme 's enhanze drugdelivery technology may allow rapid delivery large volume injectable medications ifm bms acquired outstanding shares ifm providing bms full rights ifm 's preclinical sting nlrp agonist programs focused enhancing innate immune response treating cancer biogen bms outlicensed biogen exclusive rights develop commercialize bms antietau compound development progressive supranuclear palsy roche bms outlicensed roche exclusive rights develop commercialize bms antimyostatin adnectin development duchenne muscular dystrophy cytomx bms cytomx expanded initial strategic collaboration discover novel cancer treatment therapies include eight additional targets using cytomxs proprietary probody platform treatment cancer arrangements psioxus bms acquired exclusive worldwide rights psioxus 's ng preclinical stage armed oncolytic virus goal addressing solid tumors padlock bms acquired outstanding shares padlock providing bms full rights padlocks pad inhibitor discovery program focused development treatment approaches patients ra cormorant bms acquired outstanding shares cormorant providing bms full rights cormorant 's lead candidate humaxil monoclonal antibody represents potentially complementary io mechanism action tcell directed antibodies costimulatory molecules nitto denko bms acquired exclusive worldwide license develop commercialize nitto denko 's investigational sirna molecules targeting heat shock protein hsp vitamin containing formulations including nitto denko 's lead asset ndls currently development treatment advanced liver fibrosis option receive exclusive licenses hsp sirnas vitamin containing formulations treatment lung organ fibrosis bristolmyers squibb results operations regional revenues composition changes revenues follows year ended december vs vs total revenues analysis change analysis change total foreign total foreign dollars millions change exchangeb change exchangeb united states europe rest world othera na na total revenues include royalties alliancerelated revenues products sold regional commercial organizations b foreign exchange impacts derived applying prior period average currency rates current period sales us revenues impacted higher demand opdivo eliquis partially offset lower demand established brands due increased competition primarily hiv brands daklinza higher growth rate us due additional indication approvals opdivo average us net selling prices unchanged chargebacks rebates discounts refer product revenues commentary additional information europe revenues impacted higher demand eliquis opdivo foreign exchange partially offset lower demand established brands due increased competition lower average net selling prices rest world revenues impacted lower demand established brands due increased competition lower average net selling prices foreign exchange partially offset higher demand opdivo eliquis us revenues impacted higher demand eliquis opdivo partially offset lower demand established brands due increased competition primarily daklinza hiv brands average us net selling prices approximately higher chargebacks rebates discounts refer product revenues commentary additional information europe revenues impacted higher demand opdivo eliquis partially offset lower demand daklinza due increased competition lower average net selling prices rest world revenues impacted lower demand established brands including daklinza due increased competition outlicensing mature brand product partially offset higher demand opdivo eliquis lower average net selling prices single country outside us contributed total revenues annual report gtn adjustments recognize revenue net gtn adjustments described critical accounting policies activities ending reserve balances significant category gtn adjustments follows rebates chargebacks medicaid returns discounts dollars millions cash discounts medicare rebates adjustments total balance january provision related sale made current period prior period payments returns foreign currency translation balance december provision related sale made current period prior period payments returns assetsrelated liabilities heldforsale foreign currency translation balance december reconciliation gross product sales net product sales significant category gtn adjustments follows year ended december change dollars millions vs vs gross product sales gtn adjustments chargebacks cash discounts medicaid medicare rebates rebates returns discounts adjustments total gtn adjustments net product sales gtn adjustments percentage us nonus gtn adjustments primarily function product sales volume regional payer channel mix contractual legislative discounts rebates gtn adjustments increasing higher rate gross product sales due higher us eliquis gross product sales relatively high gtn adjustment percentage result competitive pressures maintain position healthcare payer formularies allowing patients continued access medical plans bristolmyers squibb product revenues year ended december change dollars millions vs vs prioritized brands opdivo us nonus eliquis us nonus orencia us nonus sprycel us nonus yervoy us nonus empliciti us nonus established brands baraclude us nonus reyataz franchise us nonus sustiva franchise us nonus hepatitis c franchise us nonus brands us nonus total revenues us nonus change excess annual report opdivo nivolumab fully human monoclonal antibody binds pd nkt cells approved several anticancer indications including bladder blood colon head neck kidney liver lung melanoma stomach continues investigated across tumor types disease areas us revenues increased periods due higher demand higher growth rate primarily due approvals treatment adjuvant melanoma liver cancer opdivoyervoy combination kidney cancer partially offset decline lung cancer indication international revenues increased periods due higher demand result approvals additional indications launches new countries lower growth rate primarily due additional competition opdivo nsclc indication eliquis apixaban oral factor xa inhibitor targeted stroke prevention adult patients nvaf prevention treatment vte disorders us revenues increased periods due market share gains partially offset lower average net selling prices international revenues increased periods due higher demand attributed market share gains growth novel oral anticoagulants market orencia abatacept fusion protein indicated adult patients moderate severe active ra psa also indicated reducing signs symptoms certain pediatric patients moderately severely active polyarticular jia us revenues increased periods due higher demand higher average net selling prices international revenues increased periods due higher demand may experience additional competition europe biosimilars competitor products future periods sprycel dasatinib oral inhibitor multiple tyrosine kinase indicated firstline treatment adults philadelphia chromosomepositive cml chronic phase treatment adults chronic accelerated myeloid lymphoid blast phase cml resistance intolerance prior therapy including gleevec imatinib mesylate us revenues decreased due inventory workdown offset higher average net selling prices us revenues increased due higher demand higher average net selling prices international revenues remained unchanged international revenues increased due higher demand may experience decline european revenues event generic datasinib product enters market yervoy ipilimumab monoclonal antibody treatment patients unresectable metastatic melanoma us revenues increased periods due higher demand revenue growth rate decreased due lower demand resulting io products used adjuvant treatment patients melanoma including opdivo international revenues increased periods due higher demand primarily europe following approval opdivo yervoy combination therapy melanoma baraclude entecavir oral antiviral agent treatment chronic hepatitis b international revenues decreased periods due lower demand resulting increased competition reyataz atazanavir sulfate franchise includes reyataz protease inhibitor treatment hiv evotaz atazanavir mg cobicistat mg combination therapy containing reyataz tybost cobicistat loe reyataz us occurred december result revenues continue decline international revenues decreased periods due lower demand resulting increased competition sustiva efavirenz franchise nonnucleoside reverse transcriptase inhibitor treatment hiv includes sustiva antiretroviral drug bulk efavirenz also included combination therapy atripla loe sustiva us occurred december gilead terminated bms 's participation us canada joint venture following launch generic version sustiva us result bms 's share atripla revenues decline next two years refer consolidated financial statementsnote alliances discussion international revenues include million us atripla royalty revenue bristolmyers squibb hepatitis c franchise daklinza daclatasvir nsa replication complex inhibitor sunvepra asunaprevir ns protease inhibitor beclabuvir nsb inhibitor us international revenues decreased periods due lower demand resulting increased competition brands includes brands including lost exclusivity major markets otc brands royalty revenue international revenues decreased primarily due lower plavix royalties result adoption amended revenue guidance expiration rights abilify canada lower diabetes product supply sales continued generic erosion revenue decrease due outlicensing divestiture certain brands continued generic erosion estimated enduser demand pursuant sec consent order described sec consent order monitor level inventory hand us wholesaler distribution channel outside us direct customer distribution channel obligated disclose products levels inventory excess one month hand expected demand subject de minimis exception estimated levels inventory distribution channel excess one month hand following products material results operations dates indicated december daklinza months inventory hand us result minimum required stock levels support patient demand expect inventory hand levels daklinza exceed one month near term international products estimated levels inventory distribution channel excess one month hand september dafalgan analgesic product sold principally europe months inventory hand internationally direct customers compared months inventory hand june level inventory hand primarily due ordering patterns pharmacists france efferalgan analgesic product sold principally europe months inventory hand internationally direct customers compared also months inventory hand june level inventory hand primarily due ordering patterns pharmacists france fervex cold flu product months inventory hand direct customers compared months inventory hand june level inventory hand primarily due ordering patterns pharmacists france daklinza hepatitis c product months inventory hand internationally direct customers compared months inventory hand june level inventory hand attributable low volume inmarket sales canada perfalgan analgesic product months inventory hand internationally direct customers compared months inventory hand june level inventory hand primarily gulf countries due extended delivery lead time sustiva hiv product months inventory hand internationally direct customers compared months inventory hand june level inventory hand attributable low volume inmarket sales canada us generally determine months hand estimates using inventory levels product hand amount movement provided three largest wholesalers account approximately total gross sales us products factors may influence estimates include generic competition seasonality products wholesaler purchases light increases wholesaler list prices new product launches new warehouse openings wholesalers new customer stockings wholesalers addition estimates calculated using thirdparty data may impacted recordkeeping processes annual report nonus businesses significantly direct customers information available direct customer product level inventory corresponding outmovement information reliability thirdparty demand information varies widely limit direct customer sales channel inventory reporting influence demand information exist otherwise available developed variety methodologies estimate data including using historical sales made direct customers third party market research data related prescription trends enduser demand given difficulties inherent estimating thirdparty demand information evaluate methodologies estimate direct customer product level inventory calculate months hand ongoing basis make changes necessary factors may affect estimates include generic competition seasonality products price increases new product launches new warehouse openings direct customers new customer stockings direct customers expected direct customer purchases governmental bidding situations information required estimate months hand direct customer distribution channel nonus business year ended december available prior filing disclose product levels inventory excess one month hand expected demand subject de minimis exception next quarterly report form q expenses change dollar millions vs vs cost products sold marketing selling administrative research development income net total expenses cost products sold cost products sold include material internal labor overhead costs owned manufacturing sites thirdparty product supply costs supply chain costs managed global manufacturing supply organization cost products sold also includes royalties profit sharing certain excise taxes foreign currency hedge settlement gains losses amortization acquired developed technology costs cost products sold typically vary periods result product mix volume particularly royalties profit sharing lesser extent changes foreign currency price inflation costs attributed manufacturing site exits cost products sold increased due higher royalties profit sharing million resulting primarily higher eliquis sales partially offset product cost improvements million impairment charge reduce carrying value small molecule active pharmaceutical ingredient manufacturing operations swords ireland lower inventory charges cost products sold increased due higher royalties profit sharing million resulting primarily higher eliquis sales million impairment charge discussed remaining increase primarily due higher sales volume inventory charges manufacturing startup costs foreign currency marketing selling administrative marketing selling administrative expenses primarily include salary benefit costs thirdparty professional marketing fees outsourcing fees shipping handling costs advertising product promotion expenses managed regional commercialization organizations global enabling functions finance legal information technology human resources certain expenses shared alliance partners based upon contractual agreements expenses typically vary periods due new product launch promotional activities marketing selling administrative expenses decreased due lower advertising promotion marketing expenses lower costs attributed transformation initiatives lower branded prescription drug fee partially offset higher bms foundation grants marketing selling administrative expenses decreased due lower advertising promotion salesforce expenses supporting daklinza established brands lower bms foundation grants bristolmyers squibb research development research development activities include discovery research preclinical clinical development drug formulation medical support marketed products expenses include salary benefit costs thirdparty grants fees paid clinical research organizations supplies upfront contingent milestone payments licensing asset acquisitions investigational compounds iprd impairment charges proportionate allocations enterprisewide costs allocations include facilities information technology employee stock compensation costs appropriate costs certain expenses shared alliance partners based upon contractual agreements expenses typically vary periods number reasons including timing license asset acquisition charges iprd impairment charges research development expense decreased due lower site exit costs iprd impairment charges partially offset expansion opdivo io development programs including nktr research development expense increased due higher license asset acquisition charges site exit charges iprd impairment charges expansion opdivo io development programs significant charges included rd expense follows year ended december dollars millions nektar cormorant b ifm b cytomx halozyme flexus b b cardioxyl b psioxus ono padlock nitto denko license asset acquisition charges fstar iprd impairments site exit costs research development significant charges upfront payment b milestone payment license asset acquisition charges resulted strategic transactions acquire license certain investigational oncology cardiovascular immunoscience fibrotic disease compounds options acquire license disclosed acquisitions divestitures licensing collaboration arrangements iprd impairment charges includes discontinued development investigational compound part alliance fstar site exit costs resulted expected exit rd sites us primarily due reduction estimated useful lives related assets impairment charge reduce carrying value rd facility wallingford connecticut annual report income net income net decreased primarily due losses equity investments related nektar patent infringement settlement partially offset lower restructuring debt redemption charges income net increased primarily due patent infringement settlement outlicensing income partially offset lower divestiture gains related service fees higher restructuring debt redemption charges components income net follows year ended december dollars millions interest expense investment income lossgain equity investments provision restructuring litigation settlements equity net income affiliates divestiture gains royalties licensing income transition service fees pension postretirement intangible asset impairment loss debt redemption income net lossgain equity investments includes fair value adjustment million related company 's equity investment nektar restructuring charges relate changes company 's operating model drive continued success near longterm focused investment commercial opportunities key brands markets competitive agile rd organization accelerate pipeline streamline operations realign manufacturing capabilities broaden biologics capabilities reflect current future portfolio well streamline simplify smallmolecule supply network new operating model expected enable company deliver strategic financial operational flexibility necessary invest highest priorities across company aggregate restructuring charges million million incurred respectively actions including accelerated depreciation impairment charges resulting early site exits litigation settlements include million bms 's share patentinfringement settlement related merck 's pd antibody keytruda million related intellectual property product liability settlements including million recognized subsequent company 's earnings release fourth quarter divestiture gains includes divestiture multiple mature global product lines oncology infectious therapy additional contingent consideration diabetes business certain otc brands investigational hiv medicines businesses royalties licensing income includes keytruda royalties upfront licensing fees biogen roche connection outlicensing certain investigational genetically defined disease compounds contingent consideration erbitux diabetes business divestitures including transfer certain royalty rights pertaining diabetes product sales million fee amending royalty rate million salesbased milestone also included transition service fees included fees resulting divestiture diabetes investigational hiv medicines businesses pension postretirement includes interest cost expected return plan assets amortization components net periodic benefit cost credit well net charges settlements curtailments special termination benefits million million million intangible asset impairment includes million outlicensed asset obtained acquisition zymogenetics inc meet primary endpoint phase ii clinical study debt redemption loss million resulted early redemption certain longterm debt obligations bristolmyers squibb income taxes dollars millions earnings income taxes provision income taxes effective tax rate impact specified items changes effective tax rate primarily due new us tax reform legislation known tax cuts jobs act act enacted december act moved worldwide tax system quasiterritorial tax system comprised broad complex changes us tax code including limited reduced us tax rate added deemed repatriation transition tax certain foreign earnings profits generally eliminated us federal income taxes dividends foreign subsidiaries included certain income controlled foreign companies us taxable income gilti created new minimum tax referred base erosion antiabuse income tax limited certain researchbased credits eliminated domestic manufacturing deduction although many aspects act effective additional tax expense billion recognized fourth quarter upon enactment act additional expense increased effective tax rate included billion one time deemed repatriation transition tax previously untaxed post foreign earnings profits including related tax reserves earnings effectively taxed rate extent specified foreign corporations held cash certain assets rate remaining earnings profits remaining million additional tax expense included adjustment measure net deferred tax assets new us tax rate accounting reduction deferred tax assets tax rate complete december provisional tax charge deemed repatriation transition tax reduced million upon completion accounting reduced effective tax rate addition tax impact attributed specified items including nondeductible rd charges valuation allowances certain tax assets resulting equity investment losses jurisdiction tax rates increased effective tax rate considering impact specified items including transitional impacts act discussed effective tax rate decreased primarily due ongoing impact act tax reserve releases partially offset taxes attributed internal cash repatriations earnings mix high low tax jurisdictions considering impact specified items effective tax rate decreased primarily due adoption amended income tax accounting guidance related share based payments early adoption intraentity transfers assets inventory partially offset earnings mix high low tax jurisdictions refer consolidated financial statementsnote income taxes information nongaap financial measures nongaap financial measures including nongaap earnings related eps information adjusted exclude certain costs expenses gains losses specified items evaluated individual basis items adjusted considering quantitative qualitative aspects typically one following characteristics highly variable difficult project unusual nature significant results particular period indicative future operating results similar charges gains recognized prior periods likely reoccur future periods including restructuring costs accelerated depreciation impairment property plant equipment intangible assets rd charges connection acquisition licensing thirdparty intellectual property rights divestiture gains losses pension legal contractual settlement charges debt redemption gains losses among items deferred current income taxes attributed items also adjusted considering individual impact overall tax expense deductibility jurisdictional tax rates nongaap information intended portray results baseline performance supplement enhance management analysts investors ' overall understanding underlying financial performance facilitate comparisons among current past future periods example nongaap earnings eps information indication baseline performance items considered us reflective ongoing results addition information among primary indicators use basis evaluating performance allocating resources setting incentive compensation targets planning forecasting future periods information intended considered isolation substitute net earnings diluted eps prepared accordance gaap annual report specified items follows year ended december dollars millions impairment charges accelerated depreciation shutdown costs cost products sold marketing selling administrative license asset acquisition charges iprd impairments site exit costs research development lossgain equity investmentsa provision restructuring litigation settlements divestiture gains royalties licensing income pension postretirement intangible asset impairment loss debt redemption income net increase pretax income income taxes items income taxes attributed us tax reform income taxes increase net earnings noncontrolling interest increase net earnings used diluted nongaap eps calculation specified items included amounts upon adoption amended guidance recognition measurement financial assets liabilities reconciliations gaap nongaap follows year ended december dollars millions except per share data net earnings attributable bms used diluted eps calculation gaap specified items net earnings attributable bms used diluted eps calculation nongaap average common shares outstanding diluted diluted eps attributable bms gaap diluted eps attributable specified items diluted eps attributable bms nongaap bristolmyers squibb financial position liquidity capital resources net cash position follows dollars millions cash cash equivalents marketable securities current marketable securities noncurrent total cash cash equivalents marketable securities shortterm debt obligations longterm debt net cash position cash cash equivalents marketable securities held us approximately billion december remaining billion held primarily international affiliates local operating needs subject onetime deemed repatriation transition tax billion payable next eight years result us tax reform expect flexibility accessing cash future cash may generated foreign subsidiaries believe existing cash cash equivalents marketable securities together cash generated operations issuance commercial paper us sufficient satisfy normal cash requirements least next years including dividends capital expenditures milestone payments working capital deemed repatriation transition tax billion debt maturing management continuously evaluates companys capital structure ensure company financed efficiently may result repurchase common stock debt securities termination interest rate swap contracts prior maturity issuance debt securities average amount commercial paper outstanding million weightedaverage rate maximum amount commercial paper outstanding million outstanding borrowings december dividend payments billion billion dividend decisions made quarterly basis board directors annual capital expenditures approximately billion billion billion expected approximately million million continue expand biologics manufacturing capabilities facilityrelated activities example constructed new largescale biologics manufacturing facility ireland produce multiple therapies growing biologics portfolio approved commercial use early also paid billion nektar certain collaboration rights million shares common stock representing ownership interest investment portfolio includes noncurrent marketable securities subject changes fair value result interest rate fluctuations market factors investment policy establishes limits amount time maturity investments institution policy also requires investments entered corporate financial institutions meet high credit quality standards refer consolidated financial statementsnote financial instruments fair value measurements information december three revolving credit facilities totaling billion consisted day billion facility scheduled expire march two fiveyear billion facilities extended september july respectively facilities provide customary terms conditions financial covenants two billion revolving facilities extendable annually one year anniversary date consent lenders borrowings outstanding revolving facilities december connection pending acquisition celgene january entered bridge commitment letter provides billion day senior unsecured bridge loan facility also entered billion term loan credit agreement consisting billion day tranche billion threeyear tranche billion fiveyear tranche term loan reduced commitments bridge facility billion obtain additional funding issuing securities obtaining loans amount bridge facility correspondingly reduced bridge loan term loan subject customary terms conditions financial covenants amounts borrowed either bridge loan term loan prior closing pending acquisition celgene january also entered two new revolving credit facilities totaling billion day billion facility expiring january threeyear billion facility expiring january day billion facility replaced existing day billion revolving facility terminated concurrently upon effectiveness new day facility supports commercial paper borrowings facilities provide customary terms conditions financial covenants annual report borrowings outstanding two revolving facilities two billion revolving facilities february following announcement pending acquisition celgene also entered forward starting interest rate swap option contracts swaptions total notional value billion hedge future interest rate risk associated anticipated issuance longterm debt fund acquisition swaptions provide us right enter forward starting interest rate swap contracts periods years january additional regulations us could passed future including additional healthcare reform initiatives changes tax laws additional pricing laws potential importation restrictions may reduce results operations operating cash flow liquidity financial flexibility continue monitor potential impact economic conditions certain european countries related impact prescription trends pricing discounts creditworthiness customers believe economic conditions material impact liquidity cash flow financial flexibility uk voted depart eu june similar companies industry certain regulatory trade labor aspects business likely affected time however currently believe matters related financial effects material impact consolidated results operations financial position liquidity sales uk represent less consolidated revenues credit ratings january moody 's placed bms review downgrade standard poor 's placed bms creditwatch negative implications following announcement acquire celgene bms 's current longterm shortterm credit ratings assigned moody 's investors service prime respectively bms 's current longterm shortterm credit ratings assigned standard poor 's respectively longterm ratings reflect agencies ' opinion low default risk somewhat susceptible adverse effects changes circumstances economic conditions shortterm ratings reflect agencies ' opinion good extremely strong capacity timely repayment credit rating downgrade may affect interest rate debt may incur fair market value existing debt ability access capital markets generally current longterm shortterm ratings reflect impact proposed acquisition celgene cash flows following discussion cash flow activities dollars millions cash flow provided byused operating activities investing activities financing activities operating activities cash flow operating activities represents cash receipts disbursements activities investing financing activities operating cash flow derived adjusting net earnings noncontrolling interest noncash operating items gains losses attributed investing financing activities changes operating assets liabilities resulting timing differences receipts payments cash transactions recognized results operations result changes cash operating activities reflect timing cash collections customers alliance partners payments suppliers alliance partners employees customer discounts rebates tax payments ordinary course business example annual employee bonuses typically paid first quarter subsequent year addition cash collections continue impacted longer payment terms certain biologic products us primarily newer oncology products including opdivo yervoy empliciti days days longer payment terms used closely align insurance reimbursement timing physicians cancer centers following administration patients bristolmyers squibb million change cash flow operating activities compared primarily attributable higher cash collections timing payments ordinary course business approximately billion partially offset higher rd licensing collaboration payments approximately million primarily due nektar transaction lower litigation settlement proceeds approximately million primarily due merck settlement lower outlicense proceeds approximately million primarily due biogen roche transactions billion change cash flow operating activities compared primarily attributable higher cash collections timing payments ordinary course business approximately million lower income tax payments approximately billion litigation settlement proceeds approximately million primarily due merck settlement outlicensing proceeds million primarily due biogen roche transactions partially offset higher rd licensing payments approximately million primarily due cytomx halozyme nitto denko transactions higher contributions pension plans approximately million investing activities cash requirements investing activities include cash used acquisitions manufacturing facilityrelated capital expenditures purchases marketable securities original maturities greater days time purchase reduced proceeds business divestitures including royalties sale maturity marketable securities million change cash flow investing activities compared primarily attributable lower net sales maturities marketable securities maturities greater days approximately million higher net acquisition payments approximately million primarily due purchase million shares nektar common stock partially offset higher business divestiture proceeds approximately million primarily due divestiture manufacturing operations swords ireland certain mature brands billion change cash flow investing activities compared primarily attributable lower net sales marketable securities maturities greater days approximately million lower business divestiture proceeds approximately million primarily due certain otc brands investigational hiv medicines businesses higher asset acquisition payments approximately million primarily due acquisition ifm financing activities cash requirements financing activities include cash used pay dividends repurchase common stock repay longterm debt borrowings reduced proceeds exercise stock options issuance longterm debt borrowings million change cash flow financing activities compared primarily attributable lower repurchases common stock billion primarily due accelerated share repurchase agreements partially offset lower net borrowings billion primarily due issuance longterm debt used repurchase common stock billion change cash flow financing activities compared primarily attributable higher repurchase common stock billion primarily due accelerated share repurchase agreements partially offset higher net borrowing activity million primarily fund repurchase common stock annual report contractual obligations offbalance sheet arrangements payments due period contractual obligations december follows obligations expiring period dollars millions total later years shortterm borrowings longterm debt interest longterm debta operating leases purchase obligations uncertain tax positionsb deemed repatriation transition tax total c includes estimated future interest payments periodic cash settlements derivatives b includes shortterm uncertain tax benefits uncertainties regarding timing resolution c excludes pension liabilities uncertainties regarding timing resolution addition committed aggregated billion potential future research development milestone payments third parties inlicensing asset acquisitions development programs including earlystage milestones billion milestones achieved phase iii clinical studies latestage milestones billion milestones achieved post phase iii clinical studies payments generally due payable upon achievement certain developmental regulatory milestones specific timing predicted agreements also provide salesbased milestones aggregating billion would obligated pay alliance partners upon achievement certain sales levels addition royalties also certain manufacturing development commercialization obligations connection alliance arrangements practicable estimate amount obligations refer consolidated financial statementsnote alliances information regarding alliances offbalance sheet arrangements material reasonably likely become material financial condition results operations sec consent order fcpa settlement previously disclosed august entered final settlement sec concluding investigation concerning certain wholesaler inventory accounting matters settlement reached consent copy attached exhibit quarterly report form q period ended september terms consent agreed subject certain defined exceptions limit sales products sold direct customers including wholesalers distributors hospitals retail outlets pharmacies government purchasers based expected demand amounts exceed approximately one month inventory hand without making timely public disclosure change practice also agreed consent certain measures implemented including establishing formal review certification process annual quarterly reports filed sec b establishing business risk disclosure group c retaining outside consultant comprehensively study help reengineer accounting financial reporting processes publicly disclosing sales incentives offered direct customers purpose inducing purchase products excess expected demand e ensuring budget process gives appropriate weight inputs come bottom top top bottom adequately documenting process established companywide policy limit sales direct customers purpose complying consent policy includes adoption various procedures monitor limit sales direct customers accordance terms consent procedures include governance process escalate appropriate management levels potential questions concerns regarding compliance policy timely resolution questions concerns addition compliance policy monitored regular basis bristolmyers squibb maintain dsas us pharmaceutical wholesalers account nearly gross us revenues current terms dsas wholesaler customers provide us weekly information respect months hand productlevel inventories amount outmovement products three largest wholesalers currently account approximately gross us revenues inventory information received wholesalers together internal information used estimate months hand product level inventories wholesalers estimate months hand product inventory levels us businesss wholesaler customers three largest wholesalers extrapolating months hand calculated three largest wholesalers contrast nonus business significantly direct customers limited information direct customer product level inventory corresponding outmovement information reliability thirdparty demand information available varies widely accordingly rely variety methods estimate months hand product level inventories business units believe abovedescribed procedures provide reasonable basis ensure compliance consent recently issued accounting standards recently issued accounting standards refer consolidated financial statementsnote accounting policies recently issued accounting standards critical accounting policies preparation financial statements requires use estimates assumptions affect reported amounts assets liabilities reported amounts revenue expenses critical accounting policies significantly impact financial condition results operations require difficult subjective complex judgments often result need make estimates effect matters inherently uncertain uncertainty actual results may vary estimates revenue recognition accounting policy revenue recognition substantial impact reported results relies certain estimates revenue recognized following fivestep model identify customer contract identify contract 's performance obligation determine transaction price allocate transaction price performance obligation recognize revenue performance obligation satisfied revenue also reduced gtn sales adjustments discussed involve significant estimates judgment considering legal interpretations applicable laws regulations historical experience payer channel mix eg medicare medicaid current contract prices applicable programs unbilled claims processing time lags inventory levels distribution channel estimates assessed period adjusted required revise information actual experience gtn adjustments following categories gtn adjustments involve significant estimates judgments information obtained external sources refer consolidated financial statementsnote revenue discussion analysis significant category gtn sales adjustments chargebacks cash discounts us business participates programs government entities significant us department defense us department veterans affairs parties including covered entities b drug pricing program whereby pricing products extended wholesaler list price participating entities entities purchase products wholesalers lower program price wholesalers charge us difference acquisition cost lower program price accounts receivable reduced estimated amount unprocessed chargeback claims attributable sale typically within two four week time lag us certain countries cash discounts offered incentive prompt payment generally approximating sales price accounts receivable reduced estimated amount unprocessed cash discounts typically within one month time lag medicaid medicare rebates us business participates state government medicaid programs qualifying federal state government programs requiring discounts rebates participating state local government entities discounts rebates provided programs included medicaid rebate accrual medicaid rebates also extended drugs used managed medicaid plans estimated amount unpaid unbilled rebates presented liability annual report rebates discounts offered managed healthcare organizations us managing prescription drug programs medicare advantage prescription drug plans covering medicare part drug benefit also pay point service discount cms medicare part beneficiaries coverage gap donut hole estimated amount unpaid unbilled rebates discounts presented liability rebates returns discounts adjustments gtn sales adjustments include sales returns programs based applicable laws regulations individual non us countries well rebates offered managed healthcare organizations us lesser extent nonus programs include several different pricing schemes cost caps volume discounts outcomebased pricing schemes pricing clawbacks based sales individual companies aggregation companies participating specific market estimated amount unpaid unbilled rebates discounts presented liability estimated returns established products determined considering historical experience factors including levels inventory distribution channel estimated shelf life product recalls product discontinuances price changes competitive products introductions generic products introductions competitive new products lower demand following loe estimated returns new products determined considering historical sales return experience similar products within product line similar therapeutic area andor similar distribution model estimated levels inventory distribution channel projected demand estimated amount product returns presented liability use information external sources information external sources used estimate gtn adjustments estimate inventory wholesalers based projected prescription demandbased sales products historical inventory experience well analysis thirdparty information including written oral information obtained certain wholesalers respect inventory levels sell customers thirdparty market research data internal information inventory information received wholesalers product recordkeeping process excludes inventory held intermediaries sell retailers hospitals also continued practice combining retail mail prescription volume retailequivalent basis use methodology internal demand forecasts also use information external sources identify prescription trends patient demand average selling prices estimates subject inherent limitations estimates rely thirdparty information certain thirdparty information form estimates reflect limitations including lags date thirdparty information generated date receive thirdparty information pension benefits accounting pension postretirement benefit plans requires actuarial valuations based significant assumptions discount rates expected longterm rates return plan assets consultation actuaries significant assumptions others salary growth retirement turnover lump sum election rates healthcare trends mortality rates evaluated selected based expectations actual experience remeasurement date pension expense could vary within range outcomes material effect reported earnings projected benefit obligations future cash funding actual results given year may differ estimated economic factors yield high quality corporate bonds coincides cash flows plans estimated payouts used determining discount rate citi pension discount curve used us plans present value benefit obligations december us pension plans determined using discount rate assumed discount rate used determining us pension plans projected benefit obligation december reduced additional projected benefit obligation would increase approximately million expected longterm rate return plan assets estimated considering expected returns individual asset classes input external advisors also consider longterm historical returns including actual performance compared benchmarks similar investments bristolmyers squibb retirement income plan 's pension expense determined using average expected longterm rate return plan assets us plans ' pension expense determined using expected longterm rate return plan assets expected longterm rate return plan assets used determining us plans pension expense reduced expense would increase million detailed discussion retirement benefits refer consolidated financial statementsnote retirement benefits bristolmyers squibb longlived assets intangible assets intangible assets billion december including licenses million million allocated unapproved products developed technology rights million capitalized software million iprd million intangible assets assessed impairment whenever current facts circumstances warrant review although iprd assessed least annually intangible assets highly vulnerable impairment charges particularly newly acquired assets recently launched products iprd assets initially measured fair value therefore reduction expectations used valuations could potentially lead impairment common potential risks leading impairment include competition earlier expected loe pricing pressures adverse regulatory changes clinical study results delay failure obtain regulatory approval additional development costs inability achieve expected synergies higher operating costs changes tax laws macroeconomic changes complexity estimating fair value intangible assets connection impairment test similar initial valuation property plant equipment property plant equipment tested impairment whenever current facts circumstances require review including whether likely asset disposed prior estimated remaining useful life additionally longlived assets periodically reviewed determine change facts circumstances would result change estimated useful life asset possibly resulting acceleration depreciation circumstances exist estimate undiscounted future cash flows generated asset appropriate grouping assets compared carrying value determine whether impairment exists lowest level identifiable cash flows asset determined impaired loss measured based difference assets fair value carrying value expectations future cash flows subject change based upon near longterm production volumes margins generated asset well potential alternative future use accelerated depreciation impairment related charges certain manufacturing rd facilities million million million additional charges continue occur result companys restructuring actions announced assets heldforsale following criteria considered concluding assets classified heldforsale managements commitment plan sell availability immediate sale present condition initiation active program identify buyer probability completed sale within one year actively marketed sale reasonable price relation current fair value likelihood significant changes plan made plan withdrawn criteria met balance sheet date assets liabilities presented separately balance sheet heldforsale lower carrying amount fair value less costs sell longer depreciated amortized classified heldforsale classified million assets million liabilities heldforsale december related planned sale upsa consumer health business division bms manufactures markets pain treatment otc products domestic sale france export sales outside france income taxes valuation allowances recognized reduce deferred tax assets likely tax benefit realized assessment whether valuation allowance required often requires significant judgment including longrange forecasts future taxable income evaluation tax planning initiatives adjustments deferred tax valuation allowances made earnings period assessments made deferred tax assets billion december net valuation allowances billion billion december net valuation allowances billion us federal net operating loss carryforwards million december carryforwards acquired result certain acquisitions subject limitations section internal revenue code net operating loss carryforwards expire varying amounts beginning foreign state net operating loss carryforwards expired varying amounts beginning certain amounts unlimited lives discussed fully consolidated financial statementsnote income taxes provisional tax charge billion attributable onetime deemed repatriation transition tax certain foreign earnings recognized fourth quarter accounting reduction deferred tax assets tax rate complete december tax charge deemed repatriation transition tax complete december provisional tax charge deemed repatriation transition tax reduced million annual report prior mead johnson splitoff following transactions occurred internal spinoff mead johnson shares still owned us ii conversion mead johnson class b shares class shares iii conversion mead johnson company limited liability company transactions well splitoff mead johnson exchange offer qualify taxexempt transactions internal revenue code based upon private letter ruling received internal revenue service related conversion mead johnson class b shares class shares outside legal opinions certain assumptions representations covenants mead johnson relied upon regarding future conduct business matters could affect tax treatment exchange example current tax law generally creates presumption exchange would taxable us mead johnson shareholders engage transactions result greater change stock ownership four year period beginning two years exchange offer unless established exchange offer part plan series related transactions effect change ownership internal spinoff exchange offer determined qualify tax exempt transaction transaction could subject tax exchange taxable sale us market value addition negative basis excess loss account ela existed investment stock mead johnson prior transactions received opinion outside legal counsel effect likely eliminated ela part transactions taxable income respect ela tax law area complex possible even internal spinoff exchange offer tax exempt internal revenue code irs could assert additional taxable income period respect ela could exposed additional taxes occur based upon understanding internal revenue code opinion outside legal counsel tax reserve million established reducing gain disposal mead johnson included discontinued operations agreed certain tax related indemnities mead johnson set forth tax sharing agreement including certain taxes related business prior completion ipo created part restructuring facilitate ipo mead johnson also agreed indemnify us potential tax effects resulting breach certain representations discussed well certain transactions related acquisition mead johnsons stock assets liabilities established possible assessments tax authorities resulting known tax exposures including limited transfer pricing matters tax credits deductibility certain expenses liabilities represent reasonable provision taxes ultimately expected paid may need adjusted time information becomes known discussions income taxes refer consolidated financial statementsnote accounting policies recently issued accounting standardsincome taxes note income taxes contingencies normal course business subject contingencies legal proceedings claims arising business cover wide range matters including among others government investigations shareholder lawsuits product environmental liability contractual claims tax matters recognize accruals contingencies probable liability incurred amount loss reasonably estimated estimates subject uncertainties difficult predict actual results could vary estimates discussions contingencies refer consolidated financial statementsnote accounting policies recently issued accounting standardscontingencies note income taxes note legal proceedings contingencies bristolmyers squibb product pipeline developments rd programs managed portfolio basis early discovery latestage development include balance early stage latestage programs support future growth late stage rd programs phase iii development include investigational compounds initial indications additional indications formulations marketed products spending programs represent approximately annual rd expenses last three years opdivo investigational compound marketed product represented greater rd expenses last three years latestage development programs could potentially impact revenue earnings within next years regulatory approvals obtained products successfully commercialized following developments marketed products latestage pipeline product indication date developments august approval japan treatment adjuvant melanoma ec approval adjuvant treatment adult patients involvement lymph nodes july metastatic disease undergone complete resection melanoma announced results phase iii checkmate trial evaluating opdivo versus yervoy patients stage iiibc stage iv melanoma high risk recurrence following june complete surgical resection demonstrated statistically longer recurrencefree survival opdivo primary endpoint study versus yervoy minimum followup months across key subgroups including disease stages braf mutation status announced june fda lifted partial clinical hold placed checkmate randomized openlabel phase iii study evaluating addition opdivo pomalidomide juneaugust dexamethasone patients relapsed refractory multiple myeloma decision multiple myeloma follows consultation fda agreement amendments study protocol august company discontinued enrollment study following futility analysis approval china treatment locally advanced metastatic nsclc prior june platinumbased chemotherapy adult patients without egfr alk genomic tumor aberrations nsclc announced pivotal randomized phase iii checkmate trial evaluating opdivo versus docetaxel predominantly chinese population previously treated advanced april nsclc demonstrated superior overall survival benefit primary endpoint regardless pdl expression tumor histology acceptance china sbla filing patients previously treated metastatic january recurrent scchn scchn announced twoyear overall survival data checkmate phase iii study evaluating opdivo compared investigators choice chemotherapy cetuximab docetaxel opdivo april methotrexate patients recurrent metastatic scchn failure platinumbased therapy announced topline results phase iii checkmate study meet primary october endpoint overall survival opdivo versus chemotherapy patients previously treated relapsed sclc sclc fda approval first io treatment option patients metastatic sclc august whose cancer progressed platinumbased chemotherapy least one line therapy august approval japan patients mpm progressed chemotherapy approval japan every week minute infusion dose administration schedule august opdivo six indications announced preliminary data ongoing pivot phase iii study evaluating combination opdivo nektar 's investigational medicine nktr preliminary results presented american society clinical oncology reported june safety efficacy biomarker data patients enrolled phase doseescalation stage study first patients consecutively enrolled select dose expansion cohorts various phase ii ec approval every fourweek qw opdivo dosing schedule mg infused minutes option patients advanced melanoma previously treated rcc april well approval twoweek opdivo dosing option mg infused minutes replace weightbased dosing six approved monotherapy indications eu fda approval company 's sbla update opdivo dosing include mg infused march every four weeks majority approved indications well shorter minute infusion across approved indications annual report product indication date developments announced new data cohort checkmate study opdivo plus low october dose yervoy demonstrated durable clinical benefit firstline treatment patients msih dmmr mcrc crc fda approval opdivo plus lowdose yervoy treatment adult pediatric patients july years older msih dmmr mcrc progressed following treatment fluoropyrimidine oxaliplatin irinotecan announced results interim analysis phase ii checkmate trial evaluating opdivoyervoy patients mcrpc showed among asymptomatic minimally symptomatic patients whose disease progressed secondgeneration hormone therapy mcrpc february received chemotherapy cohort median followup months objective response rate additionally among patients whose disease progressed taxanebased chemotherapy cohort median followup months objective response rate announced fouryear data phase iii checkmate clinical trial continues october demonstrate durable longterm survival benefits firstline combination opdivo melanoma yervoy versus yervoy alone patients advanced melanoma approval japan opdivoyervoy combination chemotherapynaive patients may unresectable melanoma announced followup data evaluating opdivo monotherapy opdivo combination yervoy patients platinumpretreated muc results phase iii checkmate muc october trial showed patients received combination opdivo mgkg plus yervoy mg kg experienced higher objective response rate compared received opdivo mgkg plus yervoy mgkg opdivo alone announced voluntary withdrawal company 's sbla opdivo plus low dose yervoy treatment firstline advanced nsclc patients tmb greater january equal mutations per megabase data checkmate part available within pdufa goal date may announced updates regarding regulatory actions chmp eu ongoing opdivoyervoy review applications indication metastatic firstline nsclc opdivo plus lowdose yervoy patients tmb greater equal mutations per megabase october chmp requested additional information checkmate including overall nsclc survival analysis opdivoyervoy patients tmb less mutations per megabase announced results part phase iii checkmate trial evaluated opdivo plus lowdose yervoy opdivo plus chemotherapy versus chemotherapy patients june firstline nsclc pdl expression across squamous nonsquamous tumor histologies extended progressionfree survival announced ema validated type ii variation application treatment adult patients may firstline metastatic nsclc tmb greater equal mutations per megabase announced new results phase iii checkmate study showing therapy february opdivo plus lowdose yervoy continued demonstrate longterm survival benefits patients previously untreated advanced metastatic rcc announced ec approval opdivo plus lowdose yervoy previously untreated patients january intermediate poorrisk advanced rcc approval japan opdivo plus lowdose yervoy treatment unresectable august rcc metastatic rcc announced patientreported outcomes data phase iii checkmate trial intermediate poorrisk patients advanced rcc treated opdivo plus lowdose june yervoy versus sunitinib twoyear followup period reported significant sustained healthrelated quality life improvements fda approval opdivoyervoy combination previously untreated patients april intermediate poorrisk advanced rcc announced patientreported outcomes phase iii checkmate study meet november primary endpoint overall survival opdivoyervoy versus placebo maintenance sclc therapy patients extensivestage sclc completion firstline platinumbased chemotherapy announced findings largest realworld data analysis nvaf patient populations november eliquis nvaf aged older receiving direct oral anticoagulants showing eliquis associated lower rates stroke systemic embolism major bleeding rivaroxaban dabigatran bristolmyers squibb product indication date developments received positive chmp opinion polyarticular jia via subcutaneous injection orencia jia january pediatric patients two years age fda approval empliciti injection intravenous use combination pomalidomide november dexamethasone treatment adult patients multiple myeloma received least two prior therapies including lenalidomide proteasome inhibitor empliciti rrmm announced ema validated company 's type ii variation application empliciti combination pomalidomide lowdose dexamethasone treatment adult september patients multiple myeloma received least two prior therapies including lenalidomide proteasome inhibitor pi demonstrated disease progression last therapy announced ec approval sprycel tablet powder oral suspension february formulations combination chemotherapy treatment pediatric patients newly diagnosed philadelphia chromosomepositive fda expanded indication sprycel include treatment pediatric patients one december sprycel year age older newly diagnosed philadelphia chromosomepositive combination chemotherapy ec expanded indication sprycel include treatment children adolescents cml july aged year years chronic phase philadelphia chromosome positive cml include powder oral suspension ec approval advanced unresectable metastatic melanoma pediatric patients years yervoy melanoma january age older announced results phase ii study bms oral selective tyk inhibitor tyk september psoriasis delivered significant skin clearance patients moderate severe plaque inhibitor psoriasis special note regarding forwardlooking statements including documents incorporated reference written oral statements make time time contain certain forwardlooking statements within meaning section securities act amended section e exchange act identify forwardlooking statements fact use words could expect anticipate estimate target may project guidance intend plan believe words terms similar meaning expression connection discussion future operating financial performance one also identify forwardlooking statements fact relate strictly historical current facts forwardlooking statements based historical performance current expectations projections future financial results goals plans objectives involve inherent risks assumptions uncertainties including internal external factors could delay divert change next several years could cause future financial results goals plans objectives differ materially expressed implied statements statements likely relate among things goals plans objectives regarding financial position results operations cash flows market position product development product approvals sales efforts expenses performance results current anticipated products pending acquisition celgene outcome contingencies legal proceedings financial results forwardlooking statement guaranteed included important factors cautionary statements included recently filed particularly item risk factors believe could cause actual results differ materially forwardlooking statement although believe prudent plans assumptions assurance given goal plan set forth forwardlooking statements achieved readers cautioned place undue reliance statements speak date made additional risks may currently deem immaterial presently known us could also cause forwardlooking events discussed occur except otherwise required federal securities law undertake obligation release publicly updates revisions forwardlooking statements result new information future events changed circumstances otherwise date annual report quantitative qualitative disclosures market risk exposed market risk resulting changes currency exchange rates interest rates certain derivative financial instruments used available costeffective basis hedge underlying economic exposure financial instruments including derivatives subject counterparty credit risk considered part overall fair value measurement derivative financial instruments used trading purposes foreign exchange risk significant amounts revenues earnings cash flow exposed changes foreign currency rates primary net foreign currency translation exposures euro japanese yen foreign currency forward contracts used manage risk primarily arising certain intercompany purchases sales transactions also exposed foreign exchange transaction risk arising nonfunctional currency denominated assets liabilities earnings denominated nonus dollar currencies foreign currency forward contracts used offset exposures designated hedges estimate appreciation underlying currencies hedged levels us dollar variables held constant would decrease fair value foreign exchange forward contracts million million december december respectively reducing earnings remaining life contracts also exposed translation risk nonus dollardenominated net assets nonus dollar borrowings used hedge foreign currency exposures net investment certain foreign affiliates designated hedges net investments effective portion foreign exchange gains losses hedges included foreign currency translation component accumulated comprehensive loss net investment decreases equivalent value nonus debt borrowings change remeasurement basis debt would subject recognition income changes occur additional information refer consolidated financial statementsnote financial instruments fair value measurements interest rate risk use fixedtofloating interest rate swap contracts designated fair value hedges provide appropriate balance fixed floating rate debt use crosscurrency interest rate swap contracts designated hedge company 's net investment japan subsidiary fair values contracts well marketable debt securities analyzed yearend determine sensitivity interest rate changes sensitivity analysis basis point increase shortterm longterm interest rates december december expected adverse impact earnings would material estimate increase basis points longterm interest rates december december would decrease fair value longterm debt million million respectively credit risk monitor investments counterparties objective minimizing concentrations credit risk investment policy invest institutions meet high credit quality standards establishes limits amount time maturity investments individual counterparty policy also requires investments entered corporate financial institutions meet high credit quality standards use derivative instruments exposes us credit risk counterparty fails perform fair value derivative instrument contract positive counterparty fails perform collateral required party whether derivatives asset liability position policy diversifying derivatives counterparties mitigate overall risk counterparty defaults additional information refer consolidated financial statementsnote financial instruments fair value measurements bristolmyers squibb consolidated statements earnings dollars millions except per share data year ended december earnings net product sales alliance revenues total revenues cost products sold marketing selling administrative research development income net total expenses earnings income taxes provision income taxes net earnings noncontrolling interest net earnings attributable bms earnings per common share basic diluted consolidated statements comprehensive income dollars millions year ended december comprehensive income net earnings comprehensive lossincome net taxes reclassifications earnings derivatives qualifying cash flow hedges pension postretirement benefits availableforsale securities foreign currency translation total comprehensive lossincome comprehensive income comprehensive incomeloss attributable noncontrolling interest comprehensive income attributable bms accompanying notes integral part consolidated financial statements annual report consolidated balance sheets dollars millions except share per share data december assets current assets cash cash equivalents marketable securities receivables inventories prepaid expenses total current assets property plant equipment goodwill intangible assets deferred income taxes marketable securities assets total assets liabilities current liabilities shortterm debt obligations accounts payable accrued liabilities deferred income income taxes payable total current liabilities deferred income income taxes payable pension liabilities longterm debt total liabilities commitments contingencies equity bristolmyers squibb company shareholders equity preferred stock convertible series par value per share authorized million shares issued outstanding liquidation value per share common stock par value per share authorized billion shares billion issued capital excess par value stock accumulated comprehensive loss retained earnings less cost treasury stock million common shares million common shares total bristolmyers squibb company shareholders ' equity noncontrolling interest total equity total liabilities equity accompanying notes integral part consolidated financial statements bristolmyers squibb consolidated statements cash flows dollars millions year ended december cash flows operating activities net earnings adjustments reconcile net earnings net cash provided operating activities depreciation amortization net deferred income taxes stockbased compensation impairment charges pension settlements amortization divestiture gains royalties asset acquisition charges lossgain equity investments adjustments changes operating assets liabilities receivables inventories accounts payable deferred income income taxes payable net cash provided operating activities cash flows investing activities sale maturities marketable securities purchase marketable securities capital expenditures divestiture proceeds acquisition payments net cash used inprovided investing activities cash flows financing activities shortterm debt obligations net issuance longterm debt repayment longterm debt repurchase common stock dividends net cash used financing activities effect exchange rates cash cash equivalents increase cash cash equivalents cash cash equivalents beginning year cash cash equivalents end year accompanying notes integral part consolidated financial statements annual report note accounting policies recently issued accounting standards basis consolidation consolidated financial statements prepared conformity us gaap including accounts bristolmyers squibb company controlled majorityowned subsidiaries certain variable interest entities intercompany balances transactions eliminated material subsequent events evaluated disclosed report issuance date refer summary abbreviated terms end terms used throughout document alliance license arrangements assessed determine whether terms provide economic control entity requiring consolidation entity entities controlled means majority voting interest referred variable interest entities consolidated bms power direct activities variable interest entity significantly impacts economic performance obligation absorb losses right receive benefits could potentially significant entity business segment information bms operates single segment engaged discovery development licensing manufacturing marketing distribution sale innovative medicines help patients prevail serious diseases global research development organization supply chain organization responsible discovery development manufacturing supply products regional commercial organizations market distribute sell products business also supported global corporate staff functions determination single segment consistent financial information regularly reviewed chief executive officer purposes evaluating performance allocating resources setting incentive compensation targets planning forecasting future periods information product regional revenue see note revenue use estimates judgments preparation financial statements requires use management estimates judgments assumptions significant assumptions estimates determining fair value potential impairment intangible assets sales rebate return accruals legal contingencies income taxes pension postretirement benefits actual results may differ estimated results reclassifications certain prior period amounts reclassified conform current period presentation lossgain equity investments previously presented impairment charges adjustments consolidated statements cash flows presented separately revenue recognition effective january adopted asc using modified retrospective method refer note revenue detailed discussion accounting policies related revenue recognition including deferred revenue royalties refer note alliances detail regarding alliances income taxes provision income taxes includes income taxes paid payable current year plus change deferred taxes year deferred taxes result differences financial tax basis assets liabilities adjusted changes tax rates tax laws changes enacted valuation allowances recognized reduce deferred tax assets likely tax benefit realized assessment whether valuation allowance required often requires significant judgment including longrange forecast future taxable income evaluation tax planning initiatives adjustments deferred tax valuation allowances made earnings period assessments made tax benefits recognized uncertain tax position likely tax position sustained examination taxing authorities based technical merits position tax benefit recognized financial statements particular tax position based largest benefit likely realized upon settlement bristolmyers squibb cash cash equivalents cash cash equivalents include bank deposits time deposits commercial paper money market funds cash equivalents consist highly liquid investments original maturities three months less time purchase recognized cost approximates fair value marketable debt securities marketable debt securities classified availableforsale date purchase reported fair value fair value determined based observable market quotes valuation models using assessments counterparty credit worthiness credit default risk underlying security overall capital market liquidity marketable debt securities reviewed impairment assessing decline market value investment carrying value temporary considers intent ability retain investment period time sufficient allow anticipated recovery market value duration extent market value less cost investee 's financial condition investments equity securities investments equity securities readily determinable fair values recorded fair value changes fair value recorded income net investments equity securities without readily determinable fair values recorded cost minus impairment plus minus changes estimated fair value resulting observable price changes orderly transactions identical similar investment issuer changes estimated fair value investments equity securities without readily determinable fair values recorded income net investments less owned companies accounted using equity method accounting ability exercise significant influence operating financial decisions investee maintained share net income losses equity investments accounted using equity method included income net investments equity securities without readily determinable fair values investments equity accounted using equity method assessed potential impairment quarterly basis based qualitative factors inventory valuation inventories stated lower average cost market property plant equipment depreciation expenditures additions renewals improvements capitalized cost depreciation computed straightline method based estimated useful lives related assets ranging years buildings years machinery equipment fixtures current facts circumstances periodically evaluated determine carrying value depreciable assets held used may recoverable circumstances exist estimate undiscounted future cash flows generated longlived asset appropriate grouping assets compared carrying value determine whether impairment exists lowest level identifiable cash flows asset determined impaired loss measured based difference assets fair value carrying value estimate assets fair value based quoted market prices active markets available quoted market prices available estimate fair value based various valuation techniques using unobservable fair value inputs discounted value estimated future cash flows capitalized software eligible costs obtain internal use software capitalized amortized estimated useful life software acquisitions businesses acquired consolidated upon obtaining control fair value assets acquired liabilities assumed recognized date acquisition excess purchase price estimated fair values net assets acquired recognized goodwill business acquisition costs expensed incurred contingent consideration potential development regulatory approval salesbased milestones salesbased royalties included purchase price business combinations excluded asset acquisitions amounts allocated lead investigational compounds asset acquisitions expensed date acquisition annual report goodwill acquired inprocess research development intangible assets fair value acquired intangible assets typically determined using incomebased approach referred excess earnings method utilizing level fair value inputs market participant valuations assume global view considering potential jurisdictions indications based discounted aftertax cash flow projections risk adjusted estimated probability technical regulatory success iprd finitelived intangible assets including licenses developed technology rights iprd projects reach commercialization amortized straightline basis estimated useful life estimated useful lives determined considering period assets expected contribute future cash flows goodwill tested least annually impairment assessing qualitative factors performing quantitative analysis determining whether likely fair value net assets carrying amounts examples qualitative factors assessed include share price financial performance compared budgets longterm financial plans macroeconomic industry market conditions well substantial excess fair value carrying value net assets annual impairment test performed prior year relevant factor assessed individually aggregate iprd tested impairment annual basis frequently events occur circumstances change would indicate potential reduction fair values assets carrying value impairment charges recognized extent carrying value iprd determined exceed fair value finitelived intangible assets tested impairment facts circumstances suggest carrying value asset may recoverable carrying value exceeds projected undiscounted pretax cash flows intangible asset impairment loss equal excess carrying value estimated fair value discounted aftertax cash flows recognized restructuring restructuring charges recognized result actions streamline operations reduce number facilities estimating impact restructuring plans including future termination benefits exit costs requires judgment actual results could vary estimates contingencies loss contingencies legal proceedings claims may occur government investigations shareholder lawsuits product environmental liability contractual claims tax matters accruals recognized probable liability incurred amount loss reasonably estimated gain contingencies including contingent proceeds related divestitures recognized realized legal fees expensed incurred advertising product promotion costs advertising product promotion costs expensed incurred advertising product promotion costs included marketing selling administrative expenses million million million foreign currency translation foreign subsidiary earnings translated us dollars using average exchange rates net assets foreign subsidiaries translated us dollars using current exchange rates us dollar effects arise translating net assets subsidiaries changing rates recognized comprehensive lossincome research development research development costs expensed incurred clinical study costs accrued service periods specified contracts adjusted necessary based upon ongoing review level effort costs actually incurred research development costs presented net reimbursements alliance partners upfront contingent development milestone payments asset acquisitions investigational compounds also included research development expense alternative future uses bristolmyers squibb cash flow payments licensing asset acquisitions investigational compounds included operating activities well outlicensing proceeds payments acquisition ownership interest legal entity including acquisitions meet accounting definition business included investing activities well divestiture proceeds royalties consideration received subsequent related sale asset business adjustments reflected operating activities include divestiture gains losses related royalties asset acquisition charges gains losses equity investments gains losses debt redemption recently adopted accounting standards revenue contracts customers amended guidance revenue recognition adopted first quarter using modified retrospective method cumulative effect change recognized retained earnings new guidance referred asc requires entity recognize amount revenue expects entitled transfer promised goods services customers replaces existing revenue recognition standards us gaap fivestep model utilized achieve core principle identify customer contract identify contracts performance obligation determine transaction price allocate transaction price performance obligation recognize revenue performance obligation satisfied timing recognizing revenue typical net product sales customers significantly change however transaction prices longer required fixed determinable certain variable consideration might recognized prior occurrence resolution contingent event result certain revenue previously deferred prior standard transaction price fixed determinable accounted variable consideration might recognized earlier provided terms sufficient reliably estimate ultimate price expected realized estimated future royalties contingent fees related certain arrangements recognized prior third party sale event occurring extent probable significant reversal amount estimated cumulative revenue occur new guidance pertaining separation licensing rights related fee recognition significantly change timing recognizing revenue existing alliance arrangements currently generating revenue timing royalties salesbased milestones forms contingent consideration resulting divestiture businesses well royalties salesbased milestones licensing arrangements change cumulative effect accounting change resulted recognizing contract assets million million increase retained earnings net tax cumulative effect primarily attributed royalties licensing rights reacquired alliance partners expected received future eligible licensing exclusion result new guidance cumulative effect adjustment revenue approximately million lower compared would reported previous guidance refer note revenue information gains losses derecognition nonfinancial assets amended guidance gains losses derecognition nonfinancial assets asc adopted first quarter using modified retrospective method amendments clarify scope asset derecognition guidance add guidance partial sales nonfinancial assets clarify recognizing gains losses transfer nonfinancial assets contracts noncustomers certain transactions sale transfer product rights constitute business require accounting similar asc including potential recognition variable consideration amended guidance may result earlier recognition variable consideration depending facts circumstances transaction cumulative effect accounting change resulted recognizing contract assets million million increase retained earnings net tax cumulative effect primarily attributed royalties termination fees licensing rights reacquired third parties expected received future eligible licensing exclusion result new guidance cumulative effect adjustment income net approximately million lower compared would reported previous guidance annual report presentation net periodic pension postretirement benefits amended guidance requiring net periodic benefit components defined benefit pension postretirement plans service costs recorded outside income operations income adopted first quarter retrospective basis cost products sold marketing selling administrative research development expenses increased aggregate corresponding offset income net adjusted amounts upon adoption new guidance follows year ended december dollars millions reported adjusted reported adjusted cost products sold marketing selling administrative research development income net definition business amended guidance revises definition business adopted prospectively first quarter amendments provide initial screen substantially fair value gross assets acquired disposed concentrated single identifiable asset group similar identifiable assets integrated set assets activities would represent business screen met set must include input substantive process together significantly contribute ability create outputs set represent business amendment also narrows definition term output requires transfer organized work force outputs exist amended guidance may result transactions accounted assets future impact results operations dependent individual facts circumstances transaction recognition measurement financial assets liabilities amended guidance recognition measurement presentation disclosures financial instruments adopted using modified retrospective method first quarter new guidance requires fair value adjustments equity investments readily determinable fair values reported earnings new guidance also requires qualitative impairment assessment equity investments without readily determinable fair value based upon observable price changes charge earnings impairment exists cumulative effect accounting change resulted million reduction comprehensive lossincome corresponding million increase retained earnings net tax refer note income net information impact results operations accounting hedging activities amended guidance derivatives hedging adopted using modified retrospective method first quarter amended guidance revises expands items eligible hedge accounting simplifies hedge effectiveness testing changes timing recognition presentation certain hedged items certain disclosure requirements also modified hedging activities prospective basis adoption amended standard material impact companys results operations reclassification certain tax effects accumulated comprehensive income amended guidance reclassification certain tax effects accumulated comprehensive income adopted prospectively fourth quarter new guidance permits reclassification income tax effect amounts recorded within accumulated comprehensive income impacted tax cuts jobs act retained earnings company recorded cumulative effect adjustment increase accumulated comprehensive loss million corresponding increase retained earnings collaborative arrangements amended guidance clarifying interaction asc revenue contracts customers asc collaborative arrangements adopted retrospectively first quarter amended guidance clarifies certain transactions collaborative arrangement participants accounted presented revenue asc adoption amended guidance impact companys results operations bristolmyers squibb recently issued accounting standards yet adopted leases february fasb issued amended guidance lease accounting amended guidance requires recognition right ofuse asset lease liability initially measured present value future lease payments leases term longer months amended guidance adopted january modified retrospective approach company 's assessment amended guidance substantially complete including implementation leasing software system procured third party vendor gathering lease information data assessment reasonable certainty exercising renewal termination options evaluation changes enhancements processes internal controls based assessment intend elect package practical expedients adoption apply shortterm lease recognition exemption leases terms months less include option purchase underlying asset reasonably certain exercise apply portfolio approach discount real property lease liabilities using company 's incremental borrowing rate real property leases provide implicit rate lease terms vary based nature operations market dynamics country however leased facilities classified operating leases remaining lease terms years comprise approximately total lease obligation discounted value approximately million december amended guidance expected materially impact companys results operations recognition rightofuse asset lease liability sublease income material company 's results operations cumulative effect accounting change expected material company 's results operations financial instruments measurement credit losses june fasb issued amended guidance measurement credit losses financial instruments entities required use forwardlooking estimated loss model availableforsale debt security credit losses recognized allowances rather reduction amortized cost guidance effective january early adoption permitted modified retrospective approach amended guidance expected materially impact companys results operations goodwill impairment testing january fasb issued amended guidance simplifies recognition measurement goodwill impairment loss eliminating step quantitative impairment test result impairment charges required amount reporting units carrying amount exceeds fair value amount allocated goodwill guidance effective prospective basis january early adoption permitted interim annual goodwill impairment tests performed january amended guidance expected materially impact companys results operations annual report note revenue following table summarizes disaggregation revenue nature year ended december dollars millions net product sales alliance revenues revenues total revenues net product sales represent companys total revenues years ended december products sold principally wholesalers distributors lesser extent directly retailers hospitals clinics government agencies pharmacies customer orders generally fulfilled within days receipt resulting minimal order backlog contractual performance obligations usually limited transfer control product customer transfer occurs either upon shipment upon receipt product certain nonus countries considering customer obtains legal title product company obtains right payment points customers able direct use obtain substantially remaining benefits product gross revenue three largest pharmaceutical wholesalers us percentage global gross revenues follows mckesson corporation amerisourcebergen corporation cardinal health inc wholesalers initially invoiced contractual list prices payment terms typically days based customary practices country exception certain biologic products us including opdivo yervoy empliciti days days revenue reduced wholesaler list price time recognition expected chargebacks discounts rebates sales allowances product returns referred gtn adjustments reductions attributed various commercial arrangements managed healthcare organizations government programs medicare medicaid b drug pricing program containing various pricing implications mandatory discounts pricing protection wholesaler list price discounts medicare part beneficiaries coverage gap addition nonus government programs include different pricing schemes cost caps volume discounts outcomebased pricing pricing clawbacks determined sales individual companies aggregation companies participating specific market chargebacks cash discounts reflected reduction receivables settled issuance credits customer typically within one month rebates discounts adjustments including medicaid medicare reflected liability settled cash payments customer typically within various time periods ranging months one year significant judgment required estimating gtn adjustments considering legal interpretations applicable laws regulations historical experience payer channel mix current contract prices applicable programs unbilled claims processing time lags inventory levels distribution channel following table summarizes gtn adjustments year ended december dollars millions gross product sales gtn adjustmentsa chargebacks cash discounts medicaid medicare rebates rebates returns discounts adjustments total gtn adjustments net product sales includes adjustments provisions product sales made prior periods resulting changes estimates million million million years ended december respectively bristolmyers squibb alliance revenues consist primarily amounts related collaborations outlicensing arrangements arrangements evaluated whether represent contracts within scope revenue recognition guidance entirety contain aspects within scope guidance either directly reference based upon application guidance related derecognition nonfinancial assets asc performance obligations identified separated party benefit directly rights goods services either together readily available resources rights goods services highly interdependent interrelated transaction prices arrangements may include fixed upfront amounts well variable consideration contingent development regulatory milestones salesbased milestones royalties likely amount method used estimate contingent development regulatory salesbased milestones ultimate outcomes binary nature expected value method used estimate royalties broad range potential outcomes exist except instances royalties relate license variable consideration included transaction price extent significant reversal amount cumulative revenue recognized probable occurring uncertainty associated variable consideration subsequently resolved significant judgment required estimating amount variable consideration recognize assessing factors outside bmss influence likelihood regulatory success limited availability third party information expected duration time resolution lack relevant past experience historical practice offering fee concessions large number broad range possible amounts extent arrangements include multiple performance obligations separable transaction price assigned distinct performance obligation reflective relative standalone selling price recognized point time upon transfer control three types outlicensing arrangements typically utilized arrangements outlicense intellectual property another party performance obligations arrangements include license additional performance obligation supply product upon request third party collaboration arrangements include transferring license third party jointly develop commercialize product outlicensing arrangements consist single performance obligation satisfied upon execution agreement development commercialization rights transferred third party upfront fees recognized immediately included income net although contingent development regulatory milestone amounts assessed period likelihood achievement typically constrained recognized uncertainty subsequently resolved full amount milestone included income net salesbased milestones royalties recognized milestone achieved subsequent sales occur salesbased milestones included income net royalties included alliance revenue certain outlicensing arrangements may also include contingent performance obligations supply commercial product third party upon request license supply obligations accounted separate performance obligations considered distinct third party benefit license either together supply resources readily available obligations separately identifiable obligations contract accordance revenue recognition guidance considering standalone selling prices situations upfront fees contingent development regulatory milestone amounts salesbased milestone royalties allocated license recognized manner described consideration supply obligation usually based upon stipulated costplus margin contractual terms represent standalone selling price supply consideration recognized point time upon transfer control product third party included alliance revenue fee allocation license supply represents amount consideration company expects entitled satisfaction separate performance obligations although collaboration arrangements unique nature parties active participants operating activities exposed significant risks rewards depending commercial success activities performance obligations inherent arrangements may include transfer certain development commercialization rights ongoing development commercialization services product supply obligations except certain product supply obligations considered distinct accounted separate performance obligations similar manner discussed performance obligations considered distinct combined single performance obligation since transferred rights highly integrated interrelated obligation jointly develop commercialize product third party result upfront fees recognized ratably time throughout expected period collaboration activities included income net license combined development commercialization obligations contingent development regulatory milestones longer constrained recognized similar manner prospective basis royalties profit sharing recognized underlying sales profits occur included alliance revenue refer note alliances information annual report following table summarizes disaggregation revenue product region year ended december dollars millions prioritized brands opdivo eliquis orencia sprycel yervoy empliciti established brands baraclude reyataz franchise sustiva franchise hepatitis c franchise brands total revenues united states europe rest world othera total revenues revenues included royalties alliancerelated revenues products sold regional commercial organizations following table summarizes contract assets december january dollars millions december january prepaid expenses assets total contract assets contract assets primarily estimated future royalties termination fees eligible licensing exclusion therefore recognized upon adoption asc asc contract assets reduced receivables increased period underlying sales occur contingent development regulatory milestones outlicensing arrangements billion constrained recognized considering likelihood significant reversal cumulative amount revenue occurring cumulative catchup adjustments revenue affecting contract assets contract liabilities material year ended december revenue recognized performance obligation satisfied prior periods million year ended december consisting primarily royalties outlicensing arrangements revised estimates gtn adjustments related prior period sales sales commissions incremental costs obtaining customer contracts expensed incurred amortization periods would less one year note alliances bms enters collaboration arrangements third parties development commercialization certain products although arrangements unique nature parties active participants operating activities collaboration exposed significant risks rewards depending commercial success activities bms may either inlicense intellectual property owned party outlicense intellectual property party arrangements also typically include research development manufacturing andor commercial activities cover single investigational compound commercial product multiple compounds andor products various life cycle stages rights obligations parties global limited geographic regions refer collaborations alliances partners alliance partners bristolmyers squibb common activities bms alliance partners presented results operations follows bms principal end customer sale product sales included net product sales bms 's alliance partner principal end customer sale bms 's contractual share thirdparty sales andor royalty income included alliance revenues sale commercial products considered part bms 's ongoing major central operations refer note revenue information regarding recognition criteria amounts payable bms alliance partners principal end customer sale supply commercial products included alliance revenues sale commercial products considered part bms 's ongoing major central operations profit sharing royalties salesbased fees payable bms alliance partners included cost products sold incurred cost reimbursements parties recognized incurred included cost products sold marketing selling administrative expenses research development expenses based underlying nature related activities subject reimbursement upfront contingent development approval milestones payable bms alliance partners investigational compounds commercial products deferred amortized expected period bms 's development copromotion obligation market exclusivity period periods related compounds products expected contribute future cash flows amortization presented consistent nature payment arrangement example amounts received investigational compounds presented income net activities performed time related sale commercial products included bmss ongoing major central operations amounts received commercial products presented alliance revenue sale commercial products considered part bmss ongoing major central operations upfront contingent approval milestones payable bms alliance partners commercial products capitalized amortized shorter contractual term periods related products expected contribute future cash flows amortization included cost products sold upfront contingent milestones payable bms alliance partners prior regulatory approval expensed incurred included research development expense royalties contingent consideration payable bms alliance partners related divestiture businesses included income net earned payments bms alliance partners presented cash flows operating activities except otherwise described selected financial information pertaining alliances follows including net product sales bms principal thirdparty customer sale products subject alliance expenses summarized include amounts attributed activities products alliance payments alliance partners related amortization payments deferred capitalized certain prior period amounts included revised exclude amounts arrangements longer meet criteria collaboration arrangements year ended december dollars millions revenues alliances net product sales alliance revenues total revenues payments tofrom alliance partners cost products sold marketing selling administrative research development income net selected alliance balance sheet information december dollars millions receivables alliance partners accounts payable alliance partners deferred income alliancesa includes unamortized upfront milestone payments annual report specific information pertaining significant alliances discussed including nature purpose significant rights obligations parties specific accounting policy elections income statement classification amounts attributable payments parties pfizer bms pfizer jointly develop commercialize eliquis anticoagulant discovered bms pfizer funds development costs depending study profits losses shared equally global basis except certain countries pfizer commercializes eliquis pays bms salesbased fee coexclusive license rights granted pfizer exchange upfront payment potential milestone payments parties assumed certain obligations actively participate joint executive committee various operating committees joint responsibilities research development distribution sales marketing activities alliance using resources infrastructures bms pfizer manufacture product alliance bms principal end customer product sales us significant countries europe well canada australia china japan south korea bms transferred full commercialization rights pfizer certain smaller countries order simplify operations transferred countries bms supplies product pfizer cost plus percentage net sales price endcustomers recorded full upon transfer control product pfizer company allocate consideration rights transferred pfizer rights sold separately bms party could pfizer receive benefit delivered rights without fulfillment ongoing obligations bms alliance agreement global alliance treated single unit accounting upfront proceeds subsequent contingent milestone proceeds amortized expected period bms 's copromotion obligation market exclusivity period bms received million nonrefundable upfront milestone licensing payments related eliquis december amortization eliquis deferred income included income net eliquis commercial product commencement alliance summarized financial information related alliance follows year ended december dollars millions revenues pfizer alliance net product sales alliance revenues total revenues payments tofrom pfizer cost products sold profit sharing income net amortization deferred income selected alliance balance sheet information december dollars millions receivables accounts payable deferred income bristolmyers squibb otsuka bms otsuka copromote sprycel us eu parties actively participate various governance committees however bms control decision making bms responsible development manufacture product also principal end customer product sales fee paid otsuka based net sales levels oncology territory us japan eu equates million first billion annual net sales plus net sales excess billion summarized financial information related alliance follows year ended december dollars millions revenues otsuka alliances net product sales oncology territory payments otsuka cost products sold oncology fee bms also worldwide commercialization agreement otsuka codevelop copromote abilify us portion agreement expired april eu portion expired june countries bms exclusive right sell abilify expiration occurred countrybycountry basis last expiration canada january ono bms ono jointly develop commercialize opdivo yervoy several bms investigational compounds japan south korea taiwan bms responsible supply products profits losses development costs shared equally combination therapies involving compounds parties otherwise sharing activities involving one partys compounds bms ono also jointly develop commercialize orencia japan bms responsible order fulfillment distribution intravenous formulation ono responsible subcutaneous formulation formulations jointly promoted parties assigned customer accounts bms responsible product supply copromotion fee paid sale made partys assigned customer ono granted bms exclusive license development commercialization ono onos prostaglandin e receptor antagonist bms acquired worldwide rights except japan south korea taiwan added existing collaboration china asean countries ono retained exclusive rights bms paid million ono included research development expense ono eligible receive subsequent clinical regulatory salesbased milestone payments million royalties countries bms exclusive licensing rights bms provided ono right accept nktr alliance upon completion phase clinical study opdivo nktr ono territory right exercised ono partially reimburse bms development costs incurred study share certain future development costs contingent milestone payments profits losses collaboration nektar summarized financial information related alliance follows year ended december dollars millions revenues ono alliances net product sales alliance revenues total revenues bms principal end customer product sales exclusive right develop manufacture commercialize opdivo worldwide except japan south korea taiwan ono entitled receive royalties north america territories excluding three countries listed subject customary adjustments annual report gilead bms gilead operate joint venture europe develop commercialize combination product named atripla combines bms 's sustiva gilead 's truvada joint venture consolidated gilead principal end customer product sales bms receives percentage end customer sales recorded alliance revenues joint venture continue either party terminates arrangement last patent expires allows market exclusivity atripla prior bms gilead operated joint venture us canada atripla terminated following launch generic version sustiva thirdparty us result deferred income alliance receivables attributed sustiva product held joint venture december reduced million reflect posttermination selling price bms entitled fee equal atripla us net sales multiplied ratio difference average net selling prices atripla truvada atripla average net selling price fee reduced atripla us net sales multiplied ratio described bms supplies sustiva cost plus markup gilead threeyear period may terminate supply agreement notice period summarized financial information related alliance follows year ended december dollars millions revenues gilead alliances alliance revenues equity net loss affiliates nektar bms nektar commenced worldwide license collaboration development commercialization nktr nektar 's investigational immunostimulatory therapy designed selectively expand specific cancerfighting cells natural killer cells directly tumor microenvironment opdivo nktr combination therapy currently phase ii clinical studies multiple cancer indications phase iii clinical studies melanoma rcc joint development plan agreed parties contemplates development various indications tumor types party responsible supply product bms 's share development costs associated therapies comprising bms medicine used combination nktr subject certain cost caps nektar parties also jointly commercialize therapies subject regulatory approval bms 's share global nktr profits losses subject certain annual loss caps nektar bms paid nektar billion rights discussed million shares nektar common stock representing ownership interest bms 's equity ownership subject certain lockup standstill voting provisions fiveyear period amount upfront payment allocated equity investment million considering nektar 's stock price date closing current limitations trading securities remaining billion upfront payment allocated rights discussed included research development expense second quarter bms also pay billion upon achievement contingent development regulatory salesbased milestones life alliance period research development expense payable agreement nektar million year ended december bristolmyers squibb abbvie bms abbvie jointly develop commercialize empliciti humanized monoclonal antibody treatment multiple myeloma parties participate development us commercialization committees bms final decision making authority abbvie funds global development costs bms solely responsible supply distribution sales marketing activities principal end customer product sales abbvie shares profits losses us paid tiered royalties outside us abbvie also entitled receive additional million certain regulatory events occur million certain sales thresholds achieved agreement may terminated immediately bms either party material breaches subsequent notice period summarized financial information related alliance follows year ended december dollars millions revenues abbvie alliance net product sales payments abbvie cost products sold profit sharing note acquisitions divestitures licensing arrangements acquisitions acquisitions evaluated determine whether business asset group assets following transactions accounted asset acquisitions since determined business term defined asc primarily significant processes acquired result amounts allocated lead investigational compounds expensed capitalized consideration transaction upon execution last years allocated follows deferred tax contingent dollars millions year upfront payment rd expense assetsa consideration ifmb cormorant padlock relates net operating loss tax credit carryforwards b includes million certain negotiation rights collaborate license acquire nlrp antagonist program newly formed entity established former shareholders ifm ifm bms acquired outstanding shares ifm private biotechnology company focused developing therapies modulate novel targets innate immune system treat cancer autoimmunity inflammatory diseases acquisition provided bms full rights ifm 's preclinical sting nlrp agonist programs focused enhancing innate immune response treating cancer contingent consideration includes development regulatory salesbased milestone payments million included research development expense following commencement phase clinical study bms may pay million additional contingent milestones subsequent products selected ifm 's preclinical sting nlrp agonist programs included contingent consideration amount table cormorant bms acquired outstanding shares cormorant private pharmaceutical company focused developing therapies cancer rare diseases acquisition provided bms full rights cormorant 's lead candidate humaxil phase iii monoclonal antibody represents potentially complementary io mechanism action tcell directed antibodies costimulatory molecules contingent consideration includes development regulatory milestone payments million included research development expense upon conclusion month reversion option period annual report padlock bms acquired outstanding shares padlock private biotechnology company dedicated creating new medicines treat destructive autoimmune diseases acquisition provided bms full rights padlocks pad inhibitor discovery program focused development potentially transformational treatment approaches patients ra padlocks pad discovery program may additional utility treating systemic lupus erythematosus autoimmune diseases contingent consideration includes development regulatory milestone payments cardioxyl bms acquired outstanding shares cardioxyl private biotechnology company focused discovery development novel therapeutic agents cardiovascular disease acquisition provided bms full rights cxl nitroxyl prodrug phase ii development acute decompensated heart failure contingent consideration includes development regulatory salesbased milestone payments million included research development expense following commencement phase ii clinical study flexus bms acquired outstanding shares flexus private biotechnology company focused discovery development novel anticancer therapeutics acquisition provided bms full rights f preclinical small molecule idoinhibitor targeted immunotherapy addition bms acquired flexus 's idotdo discovery program includes idoselective idotdo dual tdoselective compounds contingent consideration includes development regulatory milestone payments million million included research development expense respectively following commencement phase phase ii phase iii clinical studies divestitures following table summarizes proceeds gains royalty income resulting divestitures revenue pretax earnings related divestitures assets heldforsale material periods presented excluding divestiture gains proceedsa divestiture gains royalty income dollars millions diabetes business erbitux business manufacturing operations plavix avaproavalide investigational hiv business otc business mature brands includes royalties received subsequent related sale asset business diabetes business february bms astrazeneca terminated diabetes business alliance agreements bms sold astrazeneca substantially diabetes business comprising alliance divestiture included shares amylin resulting transfer ohio manufacturing facility intellectual property related onglyza farxiga including bms 's interest outlicensing agreement onglyza japan purchase bmss manufacturing facility located mount vernon indiana consideration transaction included billion payment closing contingent regulatory salesbased milestone payments billion including million related approval milestones million related salesbased milestones payable tiered royalty payments ranging based net sales payments million certain assets transferred astrazeneca astrazeneca also pay bms required product supply price approximating product cost well negotiated transitional service fees bristolmyers squibb consideration allocated development supply agreements amortized applicable service periods amortization deferred income attributed development agreement ended december million included income net sale services considered part bmss ongoing major central operations amortization deferred income attributed supply agreement ended december recorded alliance revenues revenues attributed supply agreement included alliance revenues material royalties presented income net million million million contingent consideration million received resulting additional gain upon achievement regulatory approval milestone september bms transferred percentage future royalty rights amylin net product sales us cppib transferred rights represent approximately potential future royalties bms entitled exchange transfer bms received additional tieredbased royalty amylin net product sales us cppib royalties presented income net million million million november bms transferred percentage future royalty rights portion onglyza farxiga net product sales royalty pharma transferred rights represent approximately potential future royalties bms entitled products exchange transfer bms receive additional tieredbased royalty onglyza farxiga net product sales royalty pharma royalties presented income net million erbitux business bms commercialization agreement lilly lillys subsidiary imclone codevelopment promotion erbitux us canada japan bms principal end customer product sales north america paid lilly distribution fee erbitux net sales north america plus share certain royalties paid lilly october bms transferred rights erbitux north america lilly exchange tiered salesbased royalties september included income net royalties earned million million million bms transferred cocommercialization rights japan merck kgaa exchange salesbased royalties included income net earned royalties earned million million result adoption asc first quarter estimated future royalties resulting transfer rights merck kgaa recorded cumulative effect adjustment retained earnings subsequent changes estimates recorded income net refer note accounting policies recently issued accounting standards details manufacturing operations bms sold small molecule active pharmaceutical ingredient manufacturing operations swords ireland sk biotek approximately million subject certain adjustments initial proceeds million received first quarter transaction accounted sale business divestiture includes transfer facility majority employees site inventories certain thirdparty contract manufacturing obligations assets reduced estimated relative fair value considering purchase price resulting impairment charge million included cost products sold sk biotek provide certain manufacturing services bms plavix avaproavalide sanofi reacquired bms 's codevelopment cocommercialization agreements plavix avaproavalide consideration transfer rights included quarterly royalties december million terminal payment received million allocated optout markets million allocated bms 's interest europe asia territory partnership royalties expected received portion terminal payment allocated optout markets reflected contract asset cumulative effect adjustment upon adoption asc bms fulfilled performance obligation million allocated bms 's partnership interest deferred december recognized income net transfer sanofi refer note accounting policies recently issued accounting standards details royalties earned sanofi territory covering americas australia optout markets presented alliance revenues aggregated million million million royalties attributed territory covering europe asia earned territory partnership paid bms included equity net income affiliates amounted million million million annual report investigational hiv business bms sold investigational hiv medicines business consisting number rd programs different stages discovery development viiv healthcare bms received million also entitled receive viiv healthcare contingent development regulatory milestone payments billion salesbased milestone payments billion future tiered royalties bms earned transitional fees million million certain rd services respectively otc business bms sold reckitt otc business containing brands sold primarily mexico brazil million gain million including trademarks inventory certain assets exclusively related products manufacturing facility located mexico primarily dedicated products mature brands divestitures include several brands sold cheplapharm resulting proceeds million divestiture gains million assets heldforsale bms agreed sell upsa consumer health business billion transaction expected close second quarter accounted sale business business accounted heldforsale december accordingly assets million reclassified assets heldforsale included within prepaid expenses including million receivables million inventory million property plant equipment million goodwill additionally liabilities million reclassified liabilities related assets heldforsale included within accrued liabilities including million accrued liabilities million accounts payable million deferred tax liabilities million liabilities december bms agreed sell rd facility wallingford connecticut transaction closed accounted sale asset facility accounted heldforsale december reduced estimated relative fair value resulting impairment charge million included research development expense licensing arrangements promedior bms purchased warrant gives bms exclusive right acquire promedior biotechnology company whose lead asset prm developed treatment ipf mf warrant exercisable upon delivery phase ii data following either ipf mf phase ii clinical studies directed promedior upfront payment allocated warrant million included research development expense remaining million million upfront payment allocated promediors obligation complete phase ii studies amortized expected period phase ii studies allocation determined using level inputs bms notified promedior would exercise warrant purchase outstanding shares promedior halozyme bms halozyme entered global collaboration license agreement develop subcutaneously administered bms io medicines using halozyme 's enhanze drugdelivery technology technology may allow rapid delivery large volume injectable medications subcutaneous delivery bms paid million halozyme access technology included research development expense bms designated multiple io targets including pd develop using enhanze technology option select additional targets within five years effective date maximum targets bms may pay contingent development regulatory salesbased milestones million achieved nominated collaboration targets additional milestone payments combination products future royalties sales products using enhanze technology bristolmyers squibb cytomx bms expanded strategic collaboration cytomx discover novel therapies using cytomxs proprietary probody platform part original may collaboration discover develop commercialize probody therapeutics bms selected four oncology targets including ctla pursuant expanded agreement cytomx granted bms exclusive worldwide rights develop commercialize probody therapeutics eight additional targets bms paid cytomx million rights initial four targets expensed rd prior bms paid million cytomx access additional targets included research development expense bms also reimburse cytomx certain research costs collaboration period pay contingent development regulatory salesbased milestones million achieved collaboration target future royalties biogen bms outlicensed biogen exclusive rights develop commercialize bms antietau compound development progressive supranuclear palsy biogen paid million bms included income net bms also entitled contingent development regulatory salesbased milestone payments million achieved future royalties bms originally acquired rights compound acquisition ipierian biogen assumed bmss remaining obligations former stockholders ipierian roche bms outlicensed roche exclusive rights develop commercialize bms antimyostatin adnectin development duchenne muscular dystrophy roche paid million bms included income net bms also entitled contingent development regulatory milestone payments million achieved future royalties nitto denko bms nitto denko entered exclusive worldwide license agreement granting bms right develop commercialize nitto denko 's investigational sirna molecules targeting hsp vitamin containing formulations includes nitto denko 's lead asset ndls currently phase ii study treatment advanced liver fibrosis bms paid million nitto denko included research development expense bms may pay contingent development regulatory sales based milestones million achieved future royalties agreement also grants bms option receive exclusive licenses hsp sirnas vitamin containing formulations treatment lung fibrosis organ fibrosis fstar bms acquired exclusive option purchase fstar lead asset fs antiher antibody fragment development treatment breast gastric cancer among welldefined population herpositive patients bms discontinued development fs exercise option resulting iprd charge million included research development expense attributed noncontrolling interest annual report note income net year ended december dollars millions interest expense investment income lossgain equity investments provision restructuring litigation settlements equity net income affiliates divestiture gains royalties licensing income transition service fees pension postretirement intangible asset impairment loss debt redemption income net lossgain equity investments includes fair value adjustment million related company 's equity investment nektar litigation settlements include million bms 's share patentinfringement settlement related merck 's pd antibody keytruda royalties licensing income includes royalties resulting business divestitures intellectual property legal settlements upfront licensing fees including million biogen roche transition service fees primarily related divestiture diabetes investigational hiv medicines businesses note restructuring october company announced restructuring plan evolve streamline operating model expects incur charges connection employee workforce reductions early site exits majority charges expected incurred range billion billion consist employee termination benefit costs contract termination costs accelerated depreciation impairment charges site exit costs cash outlays connection actions expected approximately total charges charges approximately billion recognized actions since announcement including impairment charge small molecule manufacturing operation swords ireland restructuring charges recognized upon meeting certain criteria including finalization committed plans reliable estimates discussions local works councils certain markets restructuring charges addition actions recognized prior primarily related specialty care transformation initiatives designed create simplified organization across functions geographic markets addition accelerated depreciation charges incurred connection expected early exits small molecule manufacturing site cruiserath ireland rd facility wallingford connecticut refer note acquisitions divestitures licensing arrangements information employee workforce reductions approximately bristolmyers squibb following tables summarize charges activity related restructuring actions year ended december dollars millions employee termination costs termination costs provision restructuring accelerated depreciation asset impairments shutdown costs total charges year ended december dollars millions cost products sold marketing selling administrative research development income net total charges year ended december dollars millions liability january charges change estimates provision restructuring foreign currency translation payments liability december note income taxes provisionbenefit income taxes consisted year ended december dollars millions current us nonus total current deferred us nonus total deferred total provision annual report effective tax rate reconciliation effective tax rate us statutory federal income tax rate earnings income taxes dollars millions earnings income taxes us nonus total us statutory rate deemed repatriation transition tax deferred tax remeasurement global intangible low taxed income gilti foreign tax effect certain operations ireland puerto rico switzerland us federal valuation allowance us federal state foreign contingent tax matters us federal research based credits goodwill allocated divestitures us branded prescription drug fee nondeductible rd charges puerto rico excise tax domestic manufacturing deduction state local taxes net valuation allowance foreign new tax reform legislation enacted december known tax cuts jobs act act act moved worldwide tax system quasiterritorial tax system comprised broad complex changes us tax code including limited reduced us tax rate added deemed repatriation transition tax certain foreign earnings profits generally eliminated us federal income taxes dividends foreign subsidiaries included certain income controlled foreign companies us taxable income gilti created new minimum tax referred base erosion antiabuse income tax limited certain us federal research based credits eliminated domestic manufacturing deduction although many aspects act effective additional tax expense billion recognized fourth quarter upon enactment including billion onetime deemed repatriation transition tax previously untaxed post foreign earnings profits including related tax reserves earnings effectively taxed rate extent specified foreign corporations held cash certain assets rate remaining earnings profits remaining additional tax expense included adjustment measure net deferred tax assets new us tax rate provisional tax charge deemed repatriation transition tax including related tax reserves staff accounting bulletin reduced million accounting reduction deferred tax assets tax rate complete december tax charge deemed repatriation transition tax complete december prior enactment act earnings certain manufacturing operations low tax jurisdictions switzerland ireland puerto rico indefinitely reinvested result transition tax act company longer indefinitely reinvested respect undistributed earnings foreign subsidiaries provided deferred tax liability foreign state income withholding tax would apply company remains indefinitely reinvested respect financial statement basis excess tax basis foreign subsidiaries determination deferred tax liability respect basis difference practicable bms operates favorable tax grant puerto rico scheduled expire prior valuation allowance set result nektar equity investment fair value losses would considered limited capital loss us federal state foreign contingent tax matters includes million tax benefit respect lapse statutes bristolmyers squibb goodwill allocated business divestitures well us branded prescription drug fee deductible tax purposes rd charges primarily acquisition related milestone payments former shareholders deductible tax purposes include cormorant ifm flexus cardioxyl ifm flexus padlock cormorant puerto rico imposes excise tax gross company purchase price goods sold manufacturer puerto rico excise tax recognized cost products sold intraentity sale occurs us income tax purposes excise tax deductible results foreign tax credits generally recognized provision income taxes excise tax incurred deferred taxes valuation allowance components current noncurrent deferred income tax assetsliabilities follows december dollars millions deferred tax assets foreign net operating loss carryforwards state net operating loss credit carryforwards us federal net operating loss credit carryforwards deferred income milestone payments license fees pension postretirement benefits intercompany profit inventory items foreign deferred tax assets sharebased compensation total deferred tax assets valuation allowance deferred tax assets net valuation allowance deferred tax liabilities depreciation acquired intangible assets goodwill total deferred tax liabilities deferred tax assets net recognized deferred income taxes noncurrent income taxes payable noncurrent liabilities related assets heldforsale total us federal net operating loss carryforwards million december carryforwards acquired result certain acquisitions subject limitations section internal revenue code net operating loss carryforwards expire varying amounts beginning foreign state net operating loss carryforwards expire varying amounts beginning certain amounts unlimited lives december valuation allowance billion established following items billion primarily foreign net operating loss tax credit carryforwards million state deferred tax assets including net operating loss tax credit carryforwards million us federal deferred tax assets including equity fair value adjustments us federal net operating loss carryforwards annual report changes valuation allowance follows year ended december dollars millions balance beginning year provision utilization foreign currency translation acquisitions non us rate change balance end year income tax payments million million billion business conducted various countries throughout world subject tax numerous jurisdictions significant number tax returns filed subject examination various federal state local tax authorities tax examinations often complex tax authorities may disagree treatment items reported requiring several years resolve liabilities established possible assessments tax authorities resulting known tax exposures including limited transfer pricing matters tax credit deductibility certain expenses deemed repatriation transition tax liabilities represent reasonable provision taxes ultimately expected paid may need adjusted time information becomes known effect changes estimates related contingent tax liabilities included effective tax rate reconciliation reconciliation beginning ending amount gross unrecognized tax benefits follows year ended december dollars millions balance beginning year gross additions tax positions related current year gross additions tax positions related prior years gross additions tax positions assumed acquisitions gross reductions tax positions related prior years settlements reductions tax positions related lapse statute cumulative translation adjustment balance end year additional information regarding unrecognized tax benefits follows year ended december dollars millions unrecognized tax benefits recognized would impact effective tax rate accrued interest accrued penalties accrued interest penalties payable unrecognized tax benefits included either current noncurrent income taxes payable interest penalties related unrecognized tax benefits included income tax expense bms currently examination number tax authorities proposed considering proposing material adjustments tax positions issues transfer pricing certain tax credits deductibility certain expenses reasonably possible new issues raised tax authorities may require adjustments amount unrecognized tax benefits however estimate adjustments reasonably made time also reasonably possible total amount unrecognized tax benefits december could decrease range approximately million million next twelve months result settlement certain tax audits events expected change unrecognized tax benefits may result payment additional taxes adjustment certain deferred taxes andor recognition tax benefits reasonably possible new issues raised tax authorities may increase unrecognized tax benefits however estimate increases reasonably made time bms believes adequately provided open tax years tax jurisdiction bristolmyers squibb following summary major tax jurisdictions tax authorities may assert additional taxes based upon tax years currently audit subsequent years likely audited us canada france germany italy mexico note earnings per share year ended december amounts millions except per share data net earnings attributable bms used basic diluted eps calculation weightedaverage common shares outstanding basic incremental shares attributable sharebased compensation plans weightedaverage common shares outstanding diluted earnings per share basic earnings per share diluted note financial instruments fair value measurements financial instruments include cash cash equivalents marketable securities accounts receivable payable debt instruments derivatives changes exchange rates interest rates create exposure market risk certain derivative financial instruments used available costeffective basis hedge underlying economic exposure instruments qualify cash flow net investment fair value hedges upon meeting certain criteria including effectiveness offsetting hedged exposures changes fair value derivatives qualify hedge accounting recognized earnings occur derivative financial instruments used trading purposes financial instruments subject counterparty credit risk considered part overall fair value measurement counterparty credit risk monitored ongoing basis mitigated limiting amounts outstanding individual counterparty utilizing conventional derivative financial instruments entering agreements counterparties meet high credit quality standards consolidated financial statements would materially impacted counterparty failed perform according terms agreement collateral required party whether derivatives asset liability position terms agreements fair value measurements fair value financial instruments classified one following categories level inputs utilize unadjusted quoted prices active markets accessible measurement date identical assets liabilities fair value hierarchy provides highest priority level inputs level inputs utilize observable prices similar instruments quoted prices identical similar instruments nonactive markets additionally certain corporate debt securities utilize thirdparty matrix pricing model using significant inputs corroborated market data substantially full term assets equity fixed income funds primarily invested publicly traded securities valued respective nav underlying investments level derivative instruments valued using libor yield curves less credit valuation adjustments observable forward foreign exchange rates reporting date valuations derivative contracts may fluctuate considerably volatility underlying foreign currencies underlying interest rates driven market conditions duration contract level unobservable inputs used little market data available level financial assets liabilities december annual report financial assets liabilities measured fair value recurring basis summarized december december dollars millions level level level level cash cash equivalents money market securities marketable securities certificates deposit commercial paper corporate debt securities equity investments derivative assets equity investments derivative liabilities availableforsale securities changes fair value equity investments included income net upon adoption asu first quarter following table summarizes debt equity securities classified availableforsale december december gross unrealized gross unrealized amortized amortized dollars millions cost gains losses fair value cost gains losses fair value certificates deposit commercial paper corporate debt securities equity investmentsa equity investmentsb total december december dollars millions current marketable securities noncurrent marketable securitiesc assetsa total includes equity investments readily determinable fair values measured using fair value option december b includes equity fixed income funds measured using fair value option december refer note accounting policies recently issued accounting standards information c noncurrent marketable securities mature within five years december december equity investments measured fair value excluded table limited partnerships equity method investments million december million december equity investments without readily determinable fair values million december million december amounts included assets adjustments equity investments without readily determinable fair values million resulting observable price changes similar securities issuer recorded income net following table summarizes net loss recorded equity investments readily determinable fair values held december year ended dollars millions december net loss recognized less net gain recognized equity investments sold net unrealized loss equity investments held bristolmyers squibb qualifying hedges nonqualifying derivatives cash flow hedges foreign currency forward contracts used hedge certain forecasted intercompany inventory purchases sales transactions certain foreign currency transactions fair value contracts designated cash flow hedges temporarily reported accumulated comprehensive loss included earnings hedged item affects earnings upon adoption amended guidance derivatives hedging entire change fair value hedging instrument included assessment hedge effectiveness recorded derivatives qualifying cash flow hedges component comprehensive lossincome net gain loss foreign currency forward contracts expected reclassified net earnings primarily included cost products sold within next months notional amount outstanding foreign currency forward contracts primarily attributed euro billion japanese yen million december earnings impact related discontinued cash flow hedges hedge ineffectiveness significant periods presented cash flow hedge accounting discontinued forecasted transaction longer probable occurring within days originally forecasted date hedge longer effective assessments determine whether derivatives designated qualifying hedges highly effective offsetting changes cash flows hedged items performed inception quarterly basis foreign currency forward contracts designated hedging instruments used offset exposures certain foreign currency denominated assets liabilities earnings changes fair value derivatives recognized earnings occur net investment hedges nonus dollar borrowings million billion december designated hedge euro currency exposures net investment certain foreign affiliates borrowings designated net investment hedges recognized long term debt effective portion foreign exchange gain remeasurement euro debt million million respectively loss million recorded foreign currency translation component accumulated comprehensive loss related offset longterm debt january bms entered million crosscurrency interest rate swap contracts maturing december designated hedge japanese yen currency exposures company 's net investment japan subsidiary contract fair value changes recorded foreign currency translation component comprehensive lossincome related offset pension liabilities fair value hedges fixed floating interest rate swap contracts designated fair value hedges used interest rate risk management strategy create appropriate balance fixed floating rate debt contracts underlying debt hedged benchmark risk recorded fair value effective interest rate contracts onemonth libor december plus interest rate spread ranging gains losses resulting changes fair value underlying debt attributable hedged benchmark interest rate risk recorded interest expense associated offset carrying value debt since specific terms notional amount swap intended match debt hedged changes fair value swap recorded interest expense associated offset derivative asset liability consolidated balance sheet result net impact earnings underlying swap terminated prior maturity fair value adjustment underlying debt amortized reduction interest expense remaining term debt following summarizes fair value outstanding derivatives december december asseta liabilityb asseta liabilityb dollars millions notional fair value notional fair value notional fair value notional fair value derivatives designated hedging instruments interest rate swap contracts crosscurrency interest rate swap contracts foreign currency forward contracts derivatives designated hedging instruments foreign currency forward contracts included prepaid expenses assets b included accrued liabilities pension liabilities annual report following table summarizes financial statement classification amount gainloss recognized hedging instruments year ended december cost cost cost dollars millions products sold income net products sold income net products sold income net interest rate swap contracts crosscurrency interest rate swap contracts foreign currency forward contracts following table summarizes effect derivative nonderivative instruments designated hedging instruments comprehensive lossincome year ended december dollars millions derivatives qualifying cash flow hedges foreign currency forward contracts gainloss recognized comprehensive lossincomea reclassified cost products sold reclassified income net derivatives qualifying net investment hedges crosscurrency interest rate swap contracts loss recognized comprehensive lossincome nonderivatives qualifying net investment hedges non us dollar borrowings gainloss recognized comprehensive lossincome amount expected reclassified earnings next months debt obligations shortterm debt obligations include december dollars millions commercial paper nonus shortterm borrowings current portion longterm debt total average amount commercial paper outstanding million million weightedaverage interest rate respectively maximum amount commercial paper outstanding million outstanding borrowings december maximum amount commercial paper outstanding billion million outstanding borrowings december bristolmyers squibb longterm debt current portion longterm debt includes december dollars millions principal value notes due notes due notes due notes due notes due euro notes due notes due notes due euro notes due notes due notes due notes due notes due notes due maturing subtotal adjustments principal value fair value interest rate swap contracts unamortized basis adjustment swap terminations unamortized bond discounts issuance costs total current portion longterm debt longterm debt fair value longterm debt billion billion december respectively valued using level inputs based upon quoted market prices similar debt instruments fair value shortterm borrowings approximates carrying value due short maturities debt instruments senior unsecured notes issued registered public offerings notes rank equally right payment bms 's existing future senior unsecured indebtedness redeemable whole part time predetermined redemption price following table summarizes issuance longterm debt obligations none dollars millions principal value notes due notes due total proceeds net discount deferred loan issuance costs forward starting interest rate swap contracts terminated notional amount realized gain unrealized loss annual report bms repaid million notes maturity company repurchased certain longterm debt obligations interest rates ranging following summarizes debt redemption activity dollars millions principal amount carrying value debt redemption price loss debt redemptiona including acceleration debt issuance costs gain previously terminated interest rate swap contracts related fees interest payments million million million net amounts received interest rate swap contracts december company three separate revolving credit facilities totaling billion syndicate lenders including two billion facilities expiring september july extendable annually one year anniversary date consent lenders january existing day billion facility expiring march replaced new day billion facility expiring january new threeyear billion facility expiring january entered credit facilities provide customary terms conditions financial covenants borrowings outstanding revolving credit facility december available financial guarantees provided form bank overdraft facilities standby letters credit performance bonds approximately billion december standby letters credit issued financial institutions support guarantees various obligations performance bonds issued support range ongoing operating activities including sale products hospitals foreign ministries health bonds customs duties value added tax guarantees related miscellaneous legal actions note receivables december dollars millions trade receivables less chargebacks cash discounts less bad debt allowances net trade receivables alliance receivables prepaid refundable income taxes royalties vat receivables nonus receivables sold nonrecourse basis million million million aggregate receivables three pharmaceutical wholesalers us represented total trade receivables december respectively changes allowances bad debt chargebacks cash discounts follows year ended december dollars millions balance beginning year provision utilization balance end year bristolmyers squibb note inventories december dollars millions finished goods work process raw packaging materials inventories inventories assets assets include inventory expected remain hand beyond one year periods note property plant equipment leases december dollars millions land buildings machinery equipment fixtures construction progress gross property plant equipment less accumulated depreciation property plant equipment united states europe rest world total depreciation expense million million million annual minimum rental commitments noncancelable operating leases primarily real estate motor vehicles approximately million next five years aggregate million thereafter operating lease expense approximately million million million sublease income capital lease obligations material periods presented note goodwill intangible assets december estimated dollars millions useful lives goodwill intangible assets licenses years developed technology rights years capitalized software years iprd gross intangible assets less accumulated amortization total intangible assets annual report period adjustment included year ended december reduce goodwill increase accumulated comprehensive loss million attributed goodwill prior acquisitions foreign entities previously recorded correct local currency adjustment impact consolidated results operations material previously reported balance sheets amortization expense intangible assets million million million future annual amortization expense intangible assets expected approximately million million million million million intangible asset impairment charges million million million million impairment charge recorded income net outlicensed asset obtained acquisition zymogenetics inc meet primary endpoint phase ii clinical study million iprd charge recognized attributed noncontrolling interest bms declined exercise option purchase fstar note accrued liabilities december dollars millions rebates returns employee compensation benefits research development dividends royalties branded prescription drug fee liabilities related assets heldforsale litigation settlements restructuring pension postretirement benefits accrued liabilities bristolmyers squibb note equity common stock capital accumulated treasury stock excess par value comprehensive retained noncontrolling dollars shares millions shares par value stock loss earnings shares cost interest balance january net earnings comprehensive lossincome cash dividends declaredc stock repurchase program stock compensation distributions balance december accounting change cumulative effecta adjusted balance january net earnings comprehensive lossincome cash dividends declaredc stock repurchase program stock compensation variable interest entity distributions balance december accounting change cumulative effectb adjusted balance january net earnings comprehensive lossincome cash dividends declaredc stock repurchase program stock compensation adoption asu b distributions balance december cumulative effect resulting adoption asu b refer note accounting policies recently issued accounting standards additional information c cash dividends declared per common share respectively bms stock repurchase program authorized board directors allowing repurchases open market private transactions including plans established accordance rule b securities exchange act stock repurchase program expiration date may suspended discontinued time treasury stock recognized cost reacquire shares shares issued treasury recognized utilizing firstin firstout method bms repurchased billion common stock accelerated share repurchase agreements agreements funded combination debt cash annual report components comprehensive lossincome follows year ended december dollars millions pretax tax tax pretax tax tax pretax tax tax derivatives qualifying cash flow hedges unrealized gainslosses reclassified net earningsa derivatives qualifying cash flow hedges pension postretirement benefits actuarial lossesgains amortizationb settlementsb pension postretirement benefits availableforsale securities unrealized lossesgains realized gainslossesb availableforsale securities foreign currency translation total comprehensive lossincome included cost products sold b included income net accumulated balances related component comprehensive lossincome net taxes follows december dollars millions derivatives qualifying cash flow hedges pension postretirement benefits availableforsale securities foreign currency translation accumulated comprehensive loss note retirement benefits bms sponsors defined benefit pension plans defined contribution plans termination indemnity plans regular fulltime employees principal defined benefit pension plan bristolmyers squibb retirement income plan plan covering us employees representing approximately consolidated pension plan assets obligations future benefits related service plan eliminated bms contributes least minimum amount required erisa plan benefits based primarily participants years credited service final average compensation december plan assets consist primarily fixedincome securities december bms announced plans fully terminate bristolmyers squibb retirement income plan plan pension obligations related plan billion distributed combination lump sum payments eligible plan participants elect payments purchase group annuity contract athene annuity life company athene whollyowned insurance subsidiary athene holding ltd benefit obligation plan december therefore determined plan termination basis assumed portion eligible active deferred vested participants elect lump sum payments remaining obligation expected transferred athene includes annuity purchase price premium plan sufficient assets satisfy transaction obligations transaction expected close third quarter time company expects record total noncash pretax pension settlement charge approximately billion billion bristolmyers squibb net periodic benefit costcredit defined benefit pension plans includes dollars millions service cost benefits earned year interest cost projected benefit obligation expected return plan assets amortization prior service credits amortization net actuarial loss settlements curtailments special termination benefits net periodic benefit costcredit pension settlement charges recognized determining annual lump sum payments exceed annual interest service costs certain pension plans including primary us pension plan changes defined benefit pension plan obligations assets funded status amounts recognized consolidated balance sheets follows dollars millions benefit obligations beginning year service costbenefits earned year interest cost settlements curtailments actuarial gainslosses benefits paid foreign currency benefit obligations end year fair value plan assets beginning year actual return plan assets employer contributions settlements benefits paid foreign currency fair value plan assets end year funded status assetsliabilities recognized assets accrued liabilities pension liabilities funded status recognized accumulated comprehensive loss net actuarial losses prior service credit total accumulated benefit obligation defined benefit pension plans billion billion december respectively annual report additional information related pension plans follows dollars millions pension plans projected benefit obligations excess plan assets projected benefit obligation fair value plan assets pension plans accumulated benefit obligations excess plan assets accumulated benefit obligation fair value plan assets actuarial assumptions weightedaverage assumptions used determine defined benefit pension plan obligations december follows discount rate rate compensation increase weightedaverage actuarial assumptions used determine defined benefit pension plan net periodic benefit costcredit years ended december follows discount rate expected longterm return plan assets rate compensation increase yield high quality corporate bonds matching duration benefit obligations used determining discount rate citi pension discount curve used developing discount rate us plans expected return plan assets determined using expected rate return calculated value assets referred marketrelated value approximated fair value plan assets december differences assumed actual returns amortized marketrelated value straightline basis threeyear period several factors considered developing expected return plan assets including longterm historical returns input external advisors individual asset class return forecasts developed based upon market conditions example priceearnings levels yields longterm growth expectations expected longterm rate return weightedaverage target asset allocation individual asset class historical longterm actual annualized returns us pension plans follows years years years actuarial gains losses resulted changes actuarial assumptions changes discount rate revised mortality rates differences assumed actual experience differences actual expected return plan assets actuarial gains related plan benefit obligations primarily result increases discount rates actuarial losses related plan benefit obligations primarily result decreases discount rates gains losses amortized life expectancy plan participants us plans years expected remaining service periods plans extent exceed higher marketrelated value projected benefit obligation respective plan result adopting asu refer note accounting policies recently issued accounting standards details periodic benefit cost credit included income net except service cost component included cost products sold research development marketing selling administrative expenses bristolmyers squibb postretirement benefit plans comprehensive medical group life benefits provided substantially us retirees electing participate comprehensive medical group life plans lesser extent certain benefits nonus employees medical plan contributory contributions adjusted periodically vary date retirement life insurance plan noncontributory plan assets consist principally equity fixedincome securities postretirement benefit plan obligations million million december respectively fair value plan assets million million december respectively weightedaverage discount rate used determine benefit obligations december respectively net periodic benefit credits material plan assets fair value pension postretirement plan assets asset category december follows december december dollars millions level level level total level level level total plan assets equity securities equity funds fixed income funds corporate debt securities us treasury agency securities shortterm investment funds insurance contracts cash cash equivalents plan assets subject leveling plan assets measured nav practical expedient equity funds venture capital limited partnerships total plan assets measured nav practical expedient net plan assets investment valuation policies per investment class follows level inputs utilize unadjusted quoted prices active markets accessible measurement date identical assets liabilities fair value hierarchy provides highest priority level inputs instruments include equity securities equity funds fixed income funds publicly traded national securities exchange cash cash equivalents cash cash equivalents highly liquid investments original maturities three months less time purchase recognized cost approximates fair value pending trade sales purchases included cash cash equivalents final settlement level inputs utilize observable prices similar instruments quoted prices identical similar instruments nonactive markets observable inputs corroborated market data substantially full term assets liabilities equity funds fixed income funds shortterm investment funds classified level within fair value hierarchy valued nav shares held year end represents fair value corporate debt securities us treasury agency securities classified level within fair value hierarchy valued utilizing observable prices similar instruments quoted prices identical similar instruments markets active level unobservable inputs used little market data available insurance contracts held certain foreign pension plans carried contract value approximates estimated fair value based fair value underlying investment insurance company venture capital limited partnership investments typically redeemable distributions upon liquidation underlying assets significant unfunded commitments investments essentially liquidations expected occur end remaining investments using practical expedient redeemable weekly monthly basis annual report investment strategy maximize return maintaining appropriate level risk provide sufficient liquidity benefit obligations plan expenses target allocation longduration fixed income private equity adopted maintained principal defined benefit pension plan bristolmyers squibb retirement income plan bms common stock represents less plan assets december contributions estimated future benefit payments contributions pension plans million million million expected material estimated annual future benefit payments nonterminating plans including lump sum payments approximately million next five years subsequent five year period savings plans principal defined contribution plan bristolmyers squibb savings investment program contribution based employee contributions level company match expense attributed defined contribution plans us approximately million note employee stock benefit plans may shareholders approved plan replaced stock incentive plan plan provides million shares authorized grants plus shares outstanding awards plan february expire forfeited canceled withheld satisfy tax withholding obligations december million shares available award shares issued treasury stock satisfy obligations plan executive officers key employees may granted options purchase common stock less market price date option granted options generally become exercisable ratably four years maximum term ten years plan provides granting stock appreciation rights whereby grantee may surrender exercisable rights receive common stock andor cash measured excess market price common stock option exercise price company granted stock options stock appreciation rights since restricted stock units may granted key employees subject restrictions continuous employment generally vesting occurs ratably four year period grant date stock unit right receive stock end specified vesting period voting rights market share units granted executives vesting conditioned upon continuous employment vesting date payout factor least share price award date payout factor share price vesting date divided share price award date maximum share price used payout factor calculated using average closing prices grant vest date nine trading days immediately preceding grant vest date vesting occurs ratably four years performance share units granted executives three year cycle granted target number units subject adjustment number shares issued performance share units vest determined based achievement performance goals based company 's threeyear total shareholder return relative peer group companies vesting conditioned upon continuous employment occurs third anniversary grant date stockbased compensation expense awards ultimately expected vest recognized vesting period forfeitures estimated based historical experience time grant revised subsequent periods actual forfeitures differ estimates information related stockbased compensation benefits follows year ended december dollars millions restricted stock units market share units performance share units total stockbased compensation expense income tax benefit bristolmyers squibb stock options restricted stock units market share units performance share units weighted number weighted number weighted number weighted number average average average average options exercise price nonvested grantdate nonvested grantdate nonvested grantdate shares millions outstanding shares awards fair value awards fair value awards fair value balance january granted releasedexercised adjustments actual payout forfeitedcanceled balance december vested expected vest restricted market performance dollars millions stock units share units share units unrecognized compensation cost expected weightedaverage period years compensation cost recognized amounts millions except per share data weightedaverage grant date fair value per share restricted stock units market share units performance share units fair value awards vested restricted stock units market share units performance share units total intrinsic value stock options exercised fair value restricted stock units market share units performance share units approximates closing trading price bms 's common stock grant date adjusting units eligible accrued dividends addition fair value market share units performance share units considers probability satisfying payout factor total shareholder return respectively following table summarizes significant outstanding exercisable options december number weightedaverage weightedaverage aggregate outstanding exercisable remaining contractual exercise price intrinsic value millions life years per share millions options outstanding exercisable aggregate intrinsic value preceding table represents total pretax intrinsic value based closing stock price december annual report note legal proceedings contingencies company certain subsidiaries involved various lawsuits claims government investigations legal proceedings arise ordinary course business claims proceedings involve various types parties including governments competitors customers suppliers service providers licensees employees shareholders among others resolution matters often develops long period time expectations change result new findings rulings appeals settlement arrangements company recognizes accruals contingencies probable liability incurred amount loss reasonably estimated matters involve patent infringement antitrust securities pricing sales marketing practices environmental commercial contractual rights licensing obligations health safety matters consumer fraud employment matters product liability insurance coverage legal proceedings material company believes could become material described although company believes substantial defenses matters assurance increase scope pending matters future lawsuits claims government investigations legal proceedings material unless otherwise noted company unable assess outcome respective litigation able provide estimated range potential loss furthermore failure enforce patent rights would likely result substantial decreases respective product revenues generic competition intellectual property plavix australia previously disclosed sanofi notified august genrx proprietary limited genrx obtained regulatory approval application clopidogrel bisulfate mg tablets australia genrx formerly subsidiary apotex inc apotex since changed name apotex august apotex filed application federal court australia federal court seeking revocation sanofis australian patent case nsd sanofi filed counterclaims infringement sought injunction september federal court granted sanofis injunction subsidiary company subsequently added party proceedings february second company spirit pharmaceuticals pty ltd also filed revocation suit patent case consolidated apotex case trial occurred april august federal court australia held claims patent covering clopidogrel bisulfate hydrochloride hydrobromide taurocholate salts valid federal court also held process claims pharmaceutical composition claims claim directed clopidogrel pharmaceutically acceptable salts invalid company sanofi filed notices appeal full court federal court australia full court appealing holding invalidity claim covering clopidogrel pharmaceutically acceptable salts process claims pharmaceutical composition claims stayed federal courts ruling apotex filed notice appeal appealing holding validity clopidogrel bisulfate hydrochloride hydrobromide taurocholate claims hearing appeals occurred february september full court held claims patent invalid november company sanofi applied high court australia high court special leave appeal judgment full court march high court denied company sanofis request hear appeal full court decision case remanded federal court proceedings related damages sought apotex company apotex settled apotex case case dismissed australian government intervened matter seeking maximum damages million aud million plus interest would split company sanofi alleged losses experienced paying higher price branded plavix period injunction place company sanofi disputed australian government entitled damages australian government 's claim still pending trial concluded september company expecting decision sprycel europe may apotex actavis group ptc ehf generics uk limited mylan unnamed company filed oppositions epo seeking revocation european patent patent covering dasatinib active ingredient sprycel january opposition division epo revoked patent may company appealed epos decision epo board appeal february epo board appeal upheld opposition divisions decision revoked patent orphan drug exclusivity data exclusivity sprycel eu expired november epo board appeals decision affect validity sprycel patents within outside europe including different patents cover monohydrate form dasatinib use dasatinib treat cml additionally february epo board appeal reversed remanded invalidity decision european patent claim use dasatinib treat cml epos opposition division revoked october december epos opposition division upheld validity patent directed use dasatinib treat cml expires company intends take appropriate legal actions protect sprycel generics approved certain eu markets may experience decline european revenues event generic dasatinib product enters market bristolmyers squibb antipd antibody patent oppositions litigation september danafarber cancer institute danafarber filed complaint massachusetts federal court seeking correct inventorship five related us patents directed methods treating cancer using pd pdl antibodies specifically danafarber seeking add two scientists inventors patents october pfizer allowed intervene case alleging one scientists identified danafarber employed company eventually acquired pfizer relevant period february company settled lawsuit pfizer bench trial lawsuit danafarber began february decision expected eliquis patent litigation us twentyfive generic companies sent company paragraphiv certification letters informing company filed andas seeking approval generic versions eliquis result two eliquis patents listed fda orange book challenged composition matter patent claiming apixaban specifically formulation patent april company along partner pfizer initiated patent lawsuits hatchwaxman act generic filers federal district courts delaware west virginia august us patent trademark office granted patent term restoration composition matter patent thereby restoring term eliquis composition matter patent companys basis projected loe february november company settled lawsuits number anda filers december settlements affect companys projected loe eliquis pricing sales promotional practices litigation plavix state attorneys general lawsuits company certain affiliates sanofi defendants consumer protection andor false advertising actions brought several states relating sales promotion plavix product liability litigation company party various product liability lawsuits plaintiffs cases seek damages relief various grounds alleged personal injury economic loss previously disclosed addition lawsuits company also faces unfiled claims involving products byetta amylin former subsidiary company lilly codefendants product liability litigation related byetta date separate lawsuits pending behalf approximately active plaintiffs including pending settlements include injury plaintiffs well claims spouses andor beneficiaries various courts us majority cases brought individuals allege personal injury sustained using byetta primarily pancreatic cancer cases claiming alleged wrongful death majority cases pending federal court san diego mdl coordinated proceeding california superior court los angeles jccp november defendants ' motion summary judgment based federal preemption granted mdl jccp november ninth circuit reversed mdl summary judgment order remanded case mdl november california court appeal reversed state court dismissal state court cases remanded jccp proceedings amylin product liability insurance covering substantial number claims involving byetta additional liability amylin respect byetta expected shared company astrazeneca abilify company otsuka codefendants product liability litigation related abilify plaintiffs allege abilify caused engage compulsive gambling impulse control disorders cases filed state federal courts additional cases pending canada judicial panel multidistrict litigation consolidated federal court cases pretrial purposes us district court northern district florida february company otsuka entered master settlement agreement establishing proposed settlement program resolve abilify compulsivity claims filed january mdl well various state courts including california new jersey eliquis company pfizer codefendants product liability litigation related eliquis plaintiffs assert claims including claims wrongful death result bleeding allege caused use eliquis january claims remain pending mdl us district court southern district new york three cases remain pending state courts one remains pending canada cases dismissed prejudice mdl claims plaintiffs appeal second circuit court appeals company expects decision annual report onglyza company astrazeneca codefendants product liability litigation related onglyza plaintiffs assert claims including claims wrongful death result heart failure cardiovascular injuries allege caused use onglyza january claims pending state federal court behalf approximately individuals allege ingested product suffered injury significant majority claims pending federal courts february judicial panel multidistrict litigation ordered federal cases transferred mdl us district court eastern district kentucky part companys global diabetes business divestiture company sold onglyza astrazeneca february potential liability respect onglyza expected shared astrazeneca shareholder derivative litigation since december three shareholder derivative lawsuits filed new york state court certain officers directors company plaintiffs allege among things breaches fiduciary duty surrounding companys previously disclosed october civil settlement sec alleged fcpa violations china company agreed payment approximately million disgorgement penalties interest october three lawsuits dismissed company received notice appeal one dismissed lawsuits oral argument appeal dismissal scheduled february securities litigation since february two separate putative class action complaints filed us district northern district california us district court southern district new york company companys chief executive officer giovanni caforio companys chief financial officer charles bancroft certain former current executives company case california voluntarily dismissed remaining complaint alleges violations securities laws companys disclosures related checkmate clinical trial lung cancer fully briefed motion dismiss pending court company intends defend vigorously litigation litigation acquisition celgene litigation february nine complaints filed celgene shareholders us district court district delaware us district court district new jersey us district court southern district new york court chancery state delaware seeking enjoin company 's proposed acquisition celgene complaints actions name defendants celgene members celgene 's board directors four complaints also name company burgundy merger sub inc whollyowned subsidiary company formed solely purpose completing pending acquisition celgene merged celgene upon completion acquisition defendants complaints naming company defendant three styled putative class actions plaintiffs allege violations various federal securities laws breaches fiduciary duties connection acquisition celgene company separately tenth complaint styled putative class action filed court chancery state delaware behalf company 's shareholders naming members company 's board directors defendants complaint alleges members company 's board directors breached fiduciary duties company shareholders failing disclose material information pending acquisition company burgundy merger sub celgene intend defend vigorously lawsuits acquisition flexus litigation february company acquired flexus including rights ido inhibitor september incyte corporation incyte sued flexus flexus 's founders flexus defendants superior court state delaware initial subsequent amended complaints incyte alleged claims flexus defendants among others misappropriation various trade secrets relating research development incyte 's ido inhibitor november following two ahalf week trial trade secrets jury superior court delaware returned defense verdict behalf flexus defendants incyte may appeal decision average wholesale price litigation company defendant qui tam whistleblower lawsuit us district court eastern district pennsylvania us government declined intervene complaint alleges company inaccurately reported average manufacturer prices centers medicare medicaid services lower owed similar claims filed companies court denied company 's motion dismiss november bristolmyers squibb government investigations like pharmaceutical companies company certain subsidiaries subject extensive regulation national state local government agencies us countries bms operates result company time time subject various governmental inquiries investigations possible criminal charges substantial fines andor civil penalties could result government investigations environmental proceedings previously reported company party several environmental proceedings matters responsible various state federal foreign laws including cercla certain costs investigating andor remediating contamination resulting past industrial activity companys current former sites waste disposal reprocessing facilities operated third parties cercla matters respect cercla matters company responsible various state federal foreign laws company typically estimates potential costs based information obtained us environmental protection agency counterpart state foreign agency andor studies prepared independent consultants including total estimated costs site expected costsharing potentially responsible parties company accrues liabilities probable reasonably estimable company estimated share future costs sites million december represents sum best estimates best estimate reasonably made estimates minimal probable amount among range costs without taking account potential recoveries parties amount includes estimated costs additional probable loss associated previously disclosed north brunswick township high school remediation site note subsequent event january bms announced company entered definitive merger agreement bms acquire celgene terms agreement merger completed celgene shareholders receive one share bms common stock cash share celgene common stock held celgene shareholders also receive one tradeable contingent value right share celgene representing right receive cash subject achievement future regulatory milestones based closing price share bms common stock january recent trading day prior date announcement merger consideration represented approximately billion amount consideration received celgene stockholders fluctuate changes price shares bms common stock bms expects fund transaction combination existing cash new debt bms also expects enter accelerated share repurchase program approximately billion subject closing transaction market conditions board directors ' approval company expects transaction close end third quarter subject approval bristolmyers squibb celgene shareholders satisfaction customary closing conditions regulatory approvals annual report note selected quarterly financial data unaudited dollars millions except per share data first quarter second quarter third quarter fourth quarter year total revenues gross margin net earnings net earningsloss attributable noncontrolling interest bms earnings per share basica earnings per share diluteda cash dividends declared per common share cash cash equivalents marketable securitiesb total assets longterm debtc equity dollars millions except per share data first quarter second quarter third quarter fourth quarter year total revenues gross margin net earnings net earningsloss attributable noncontrolling interest bms earningsloss per share basica earningsloss per share diluteda cash dividends declared per common share cash cash equivalents marketable securitiesb total assets longterm debtc equity earnings per share quarters may add amounts year period computed discrete basis b marketable securities includes current noncurrent assets c longterm debt includes current portion bristolmyers squibb following specified items affected comparability results first second third fourth dollars millions quarter quarter quarter quarter year cost products solda marketing selling administrative license asset acquisition charges site exit costs research development lossgain equity investments provision restructuring litigation settlements divestiture gains royalties licensing income pension postretirement intangible asset impairment income net increasedecrease pretax income income taxes items income taxes attributed us tax reform income taxes increasedecrease net earnings first second third fourth dollars millions quarter quarter quarter quarter year cost products solda marketing selling administrative license asset acquisition charges iprd impairments site exit costs research development provision restructuring litigation settlements divestiture gains royalties licensing income pension postretirement loss debt redemption income net increasedecrease pretax income income taxes items income taxes attributed us tax reform income taxes increasedecrease net earnings noncontrolling interest increasedecrease net earnings attributable bms specified items cost products sold accelerated depreciation asset impairment shutdown costs annual report reports management managements responsibility financial statements management responsible preparation integrity financial information presented annual report accompanying consolidated financial statements prepared conformity united states generally accepted accounting principles applying certain estimates judgments required managements opinion consolidated financial statements present fairly companys financial position results operations cash flows audit committee board directors meets regularly internal auditors deloitte touche llp dt companys independent registered accounting firm management review accounting internal control structure financial reporting matters internal auditors dt full free access audit committee set forth companys standard business conduct ethics company firmly committed adhering highest standards moral ethical behavior business activities managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting supervision participation management including chief executive officer chief financial officer management assessed effectiveness internal control financial reporting december based framework internal controlintegrated framework issued committee sponsoring organizations treadway commission based assessment management concluded companys internal control financial reporting effective december provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance united states generally accepted accounting principles due inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate deloitte touche llp independent registered public accounting firm audited companys financial statements included report issued report effectiveness companys internal control financial reporting december included herein giovanni caforio chief executive officer charles bancroft chief financial officer february bristolmyers squibb controls procedures evaluation disclosure controls procedures december management carried evaluation supervision participation chief executive officer chief financial officer effectiveness design operation disclosure controls procedures defined exchange act rules ae de end period covered based evaluation management concluded december disclosure controls procedures effective managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting defined exchange act rule af supervision participation management including chief executive officer chief financial officer management assessed effectiveness internal control financial reporting december based framework internal controlintegrated framework issued committee sponsoring organizations treadway commission based assessment management concluded companys internal control financial reporting effective december provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance united states generally accepted accounting principles due inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate deloitte touche llp independent registered public accounting firm audited companys financial statements included report issued report effectiveness companys internal control financial reporting december included herein changes internal control financial reporting changes company 's internal control financial reporting quarter ended december materially affected reasonable likely materially affect company 's internal control financial reporting information february company 's amendment registration statement form company 's pending acquisition celgene company disclosed starboard value lp sent notice nomination five directors company 's board directors company informed starboard value would review connection delivery notice starboard value requested meet company 's management pending discussions notice meetings kept confidential company 's management subsequently met starboard value multiple occasions vote potential changes companys board directors would come annual meeting shareholders date set time filing company 's shareholders expected vote proposed acquisition celgene april annual report report independent registered public accounting firm shareholders board directors bristolmyers squibb company opinion financial statements audited accompanying consolidated balance sheets bristolmyers squibb company subsidiaries company december related consolidated statements earnings comprehensive income cash flows three years period ended december related notes collectively referred financial statements opinion financial statements present fairly material respects financial position company december results operations cash flows three years period ended december conformity accounting principles generally accepted united states america also audited accordance standards public company accounting oversight board united states pcaob company 's internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission report dated february expressed unqualified opinion company 's internal control financial reporting basis opinion financial statements responsibility company 's management responsibility express opinion company 's financial statements based audits public accounting firm registered pcaob required independent respect company accordance us federal securities laws applicable rules regulations securities exchange commission pcaob conducted audits accordance standards pcaob standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement whether due error fraud audits included performing procedures assess risks material misstatement financial statements whether due error fraud performing procedures respond risks procedures included examining test basis evidence regarding amounts disclosures financial statements audits also included evaluating accounting principles used significant estimates made management well evaluating overall presentation financial statements believe audits provide reasonable basis opinion parsippany new jersey february served company 's auditor since bristolmyers squibb report independent registered public accounting firm shareholders board directors bristolmyers squibb company opinion internal control financial reporting audited internal control financial reporting bristolmyers squibb company subsidiaries company december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso opinion company maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework issued coso also audited accordance standards public company accounting oversight board united states pcaob consolidated financial statements year ended december company report dated february expressed unqualified opinion consolidated financial statements basis opinion companys management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying management 's report internal control financial reporting responsibility express opinion companys internal control financial reporting based audit public accounting firm registered pcaob required independent respect company accordance us federal securities laws applicable rules regulations securities exchange commission pcaob conducted audit accordance standards pcaob standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk performing procedures considered necessary circumstances believe audit provides reasonable basis opinion definition limitations internal control financial reporting companys internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate parsippany new jersey february annual report performance graph following graph compares cumulative total stockholders ' returns common shares cumulative total stockholders ' returns companies listed standard poor 's index composite peer group major pharmaceutical companies comprised abbvie amgen astrazeneca biogen celgene gilead glaxosmithkline johnson johnson lilly merck novartis pfizer roche sanofi graph assumes investment december common shares sp index stock peer group companies including reinvestment dividends years ended december stock price performance following graph necessarily indicative future stock price performance bristolmyers squibb sp peer group bristolmyers squibb five year financial summary amounts millions except per share data income statement data total revenues net earnings net earningsloss attributable noncontrolling interest bms net earnings per common share attributable bms basic diluted average common shares outstanding basic diluted cash dividends paid bms common preferred stock cash dividends declared per common share financial position data december cash cash equivalents marketable securitiesa total assets longterm debta equity includes current noncurrent portion annual report summary abbreviated terms bristolmyers squibb company consolidated subsidiaries may referred bristolmyers squibb bms company us unless context otherwise indicates throughout used terms defined annual report fiscal year ended december libor london interbank offered rate abbvie abbvie inc lilly eli lilly company acute lymphoblastic leukemia loe loss exclusivity amgen amgen inc mcrc metastatic colorectal cancer amylin amylin pharmaceuticals inc mcrpc metastatic castrationresistant prostate cancer anda abbreviated new drug application mdl multidistrict litigation asean association southeast asian nations mead johnson mead johnson nutrition company astrazeneca astrazeneca plc merck merck co inc biogen biogen inc mf myelofibrosis cardioxyl cardioxyl pharmaceuticals inc mpm malignant pleural mesothelioma us comprehensive environmental response compensation cercla msih high microsatellite instability liability act celgene celgene corporation muc metastatic urothelial carcinoma chmp committee medicinal products human use nav net asset value cml chronic myeloid leukemia nektar nektar therapeutics cormorant cormorant pharmaceuticals nitto denko nitto denko corporation cppib credit europe sarl luxembourg private limited liability cppib nkt natural killer company crc colorectal cancer novartis novartis pharmaceutical corporation cytomx cytomx therapeutics inc nsclc nonsmall cell lung cancer dmmr dna mismatch repair deficient nvaf nonvalvular atrial fibrillation dsa distribution services agreement ono ono pharmaceutical co ltd ec european commission otc overthecounter ema european medicines agency otsuka otsuka pharmaceutical co ltd epo european patent office pad proteinpeptidyl arginine deiminase eps earnings per share padlock padlock therapeutics inc erisa employee retirement income security act pd programmed death receptor eu european union pfizer pfizer inc fasb financial accounting standards board promedior promedior inc fcpa foreign corrupt practices act psa prostatespecific antigen fda us food drug administration psioxus psioxus therapeutics ltd flexus flexus biosciences inc rd research development fstar fstar alpha ltd ra rheumatoid arthritis gaap us generally accepted accounting principles rcc renal cell carcinoma gilead gilead sciences inc reckitt reckitt benckiser group plc glaxosmithkline glaxosmithkline plc roche roche holding ag gtn grosstonet sanofi sanofi sa halozyme halozyme therapeutics inc sbla supplemental biologics license application hiv human immunodeficiency virus scchn squamous cell carcinoma head neck ifm ifm therapeutics inc sclc small cell lung cancer imclone imclone systems incorporated sec us securities exchange commission io immunooncology sk biotek sk biotek co ltd ipf idiopathic pulmonary fibrosis plan stock award incentive plan ipierian ipierian inc us united states iprd inprocess research development uk united kingdom janssen janssen pharmaceuticals inc vte venous thromboembolic jia juvenile idiopathic arthritis bristolmyers squibb board directors giovanni caforio md dinesh c paliwal chairman board chief executive officer president chief executive officer bristolmyers squibb harman international b c peter j arduini president chief executive officer theodore r samuels integra lifesciences holdings corporation former president capital guardian c trust company b robert bertolini former president chief financial officer vicki l sato phd bausch lomb former chief financial officer lead independent director bristolmyers squibb scheringplough independent chairman board denali b therapeutics inc former professor management practice molecular cell biology harvard matthew w emmens university former chief executive officer chairman b board shire plc former president chief executive officer chairman vertex gerald l storch pharmaceuticals former chief executive officer chief executive officer storch advisors former astra merck vice chairman target former chairman chief c executive officer toys r us former principal mckinsey company michael grobstein c former vice chairman ernst young llp c karen h vousden phd chief scientist cancer research uk former chief alan j lacy executive officer beatson institute cancer trustee fidelity funds former chairman research dave busters entertainment inc b audit committee b committee directors corporate governance c compensation management development committee science technology committee bristolmyers squibb leadership team giovanni caforio md ann powell judge chairman board senior vice president chief executive officer chief human resources officer charles bancroft sandra leung executive vice president chief financial executive vice president officer global business operations general counsel paul biondi thomas j lynch jr md senior vice president executive vice president strategy business development chief scientific officer chris boerner phd lou schmukler executive vice president senior vice president president chief commercial officer global product development supply adam dubow paul von autenried senior vice president senior vice president chief compliance ethics officer chief information officer john elicker senior vice president corporate affairs investor relations bristolmyers squibb stockholder information common stock product names company programs ticker symbol bmy free copy companys annual global products company program new york stock exchange report fiscal year names appearing throughout italics ended december contact referred herein registered stockholder services approved us trademarks unless corporate secretary specifically noted otherwise inquiries concerning stockholder bristolmyers squibb company accounts stock transfer matters e th street fl abilify trademark otsuka including address changes new york ny pharmaceutical co ltd elimination duplicate mailings shareowner services plus plansm also available adcetris trademark seattle directed companys investorbmscom genetics inc transfer agent registrar recent certifications atripla truvada tybost trademarks companys chief executive officer chief gilead sciences inc andor one eq shareowner services financial officer pursuant section affiliates centre pointe curve suite sarbanesoxley act filed mendota heights mn exhibits companys avaproavalide known eu company also filed new york aprovelkarvea plavix wwwshareowneronlinecom stock exchange recent annual trademarks sanofi within us ceo certification required section byetta trademarks amylin outside us aa new york stock exchange pharmaceuticals llc listed company manual telecommunications relay service enhanze trademark halozyme inc used hearing impaired additional information calling telephone numbers erbitux trademark imclone llc information following subjects farxiga onglyza trademarks shareowner services plus plansm available wwwbmscom astrazeneca ab shareowner services plus plansm bristolmyers squibb foundation designed longterm investors wish clinical trials gleevec trademark novartis ag build share ownership companys compliance ethics ixempra trademark rpharm common stock time partici diversity workforce statistics us operating llc pate plan registered holder companys common stock patient assistance programs keytruda trademark merck sharp companys common stock policy advocacy engagement dohme corp become participant making political contributions prostvac trademark bn initial purchase plan plan sustainabilityenvironmental programs immunotherapeutics inc features dividend reinvestment optional cash purchase share safekeeping annual report contains certain secure future trademark share sales transfers bristolmyers forwardlooking information within bristolmyers squibb squibb company appointed eq share meaning private securities litigation brand names products owner services administrator plan reform act forwardlooking italicized letters without asterisk plan sponsored administered statements based current expec registered trademarks bristolmyers bristolmyers squibb company tations involve inherent risks squibb andor one subsidiaries uncertainties could cause actual comes results differ materially current expectations please see financial review discussion description risks uncertainties company undertakes obligation publicly update forwardlooking statement whether result new information future events otherwise shareowner services plus plan service mark eq shareowner services patient story waiting breakthrough samantha wesson havent let disease stop living life fullest samantha wesson one countless shortlived body patients waiting breakthrough adapted rejected treatments usually one yearold wife mother two years poughkeepsie new york samantha suffers psoriasis incurable autoimmune recently samantha developed disease skin cells build form painful joint pain associated scales itchy often painful dry patches psoriatic arthritis sometimes psoriatic arthritis form arthritis pain knees ankles affects people psoriasis makes difficult get bed says ive covered head toe ugly painful itching pretty despite many hardships devastating samantha says samantha endured samantha husband paul credits support remains positive optimistic like patients samantha developed family friends strength stay hopeful never let disease control psoriasis first age developed despite autoimmune disorder life says support psoriatic arthritis later life struggled since age family friends havent unfortunately people society judge others let stop living life fullest appearance first psoriasis appeared behind ears according samantha progress new treatment options means scalp says samantha young girl almost everyone hope patients psoriasis symptoms terribly embarrassing people think condition want thank everyone working find breakthrough contagious isnt says would mean everything bring relief family wait hope new treatment samantha began treat symptoms creams various works medications little effect disease progressed turned treatments including biologics bristolmyers squibb recently enrolled phase clinical trial provided relief however breaks suffering tyk inhibitor psoriasis bristolmyers squibb company rights reservedbmscom bristolmyers squibb bmsnews bristolmyers squibb bristolmyers squibb e th street fl new york ny troper launna bbiuqs sreymlotsirb